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Abstract 
 
Neurodegenerative diseases are one of the major world causes of morbidity and 
mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic 
proportions. These disorders form a heterogeneous group, ranging from multi-factorial 
dementias to rare monogenic inherited proteopathies, but they all are progressive and so far 
lethal, since there are no disease-modifying therapies presently available. Therefore, major 
research efforts are in progress for developing effective therapies, but in order to achieve 
this goal there is an imperative need of consistent tools for diagnosis, prognosis and 
monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these 
requirements and its research is a rapidly advancing field, supported by some cases of 
success for other diseases, in different fields like oncology and cardiology. Pathological 
alterations in the brain or central nervous system could be monitored by analysis of 
cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, 
almost none have reached validation and for that reason they are still not used in clinical 
routine. Several problems regarding lack of longitudinal studies or reproducibility between 
reports are still waiting to be solved. In a near future this could happen by more intensive 
collaboration between research centers, industry and government in different countries, in 
joint initiatives. This review summarizes the most relevant CSF biomarker candidates for 
Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and 
Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, 
beyond the current limitations in this investigation area. 
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1. Introduction 
 
Given the dramatic raise in life expectancy in the last century that is leading to rapidly 
aging populations across the world, the incidence and prevalence of neurodegenerative 
disorders is steadily increasing, reaching epidemic proportions. In fact, epidemiologic studies 
suggest that prevalence rates could double every 5 years after age 65 (Montine et al., 2009). 
For dementia only, previsions are that it will double every 20 years during the first half of 
this century, increasing from approximately 35 million in 2010 to almost 120 million in 2050 
(The Alzheimer’s Study Group Report, 2008). These diseases are major causes of morbidity 
and mortality and have an enormous economic and social impact not only in patients and 
their families, but also in healthcare systems globally (Trojanowski et al., 2011). This scenario 
justifies the major research efforts seen nowadays not only for effective therapies but also 
for the search of etiologies, pathogenic mechanisms and biomarkers that altogether can 
contribute to reducing the burden of such disorders. 
Neurodegenerative diseases are generally defined as hereditary and sporadic conditions 
which are characterized by progressive loss of functions of the nervous system, often 
associated with atrophy of the affected central or peripheral structures (Mattsson, 2011). 
Another common feature that appears to be involved is the aggregation of different 
misfolded proteins, the reason for they are often called proteopathies. Despite the fact that 
they form a heterogeneous group, they all are progressive and lethal, since there is neither 
cure nor disease-modifying therapies currently available. 
The most common symptoms are cognitive impairment and dementia, but movement 
disorders are also frequent. Thus, the conditions range from dementia caused by Alzheimer’s 
disease (AD), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), 
among others, to diseases leading mainly to motor impairment like Parkinson’s disease (PD) 
and amyotrophic lateral sclerosis (ALS). In addition to those multi-factorial disorders, some 
of these are also monogenicaly inherited, such as polyglutamine diseases, caused by the 
expansion of a CAG repeat encoding glutamine within the open reading frame of different 
genes, comprising Huntington’s disease (HD) or Machado Joseph disease (MJD), to name a 
few. Additionally, some of these disorders may occur concomitantly and some overlap 
pathologically or clinically (Shaw et al., 2007). 
Despite the intensive research in the area and the urgent need of disease-modifying 
therapies, several problems remain to be solved in order to successfully achieve this goal. 
Usually, neurodegenerative diseases follow a slowly chronic progressive course and the first 
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symptoms appear only when the degenerative process has progressed for a long time 
(Noelker et al., 2011). Moreover, the diagnosis of the majority of these diseases is based, so 
far, on clinical signs  (confirmed by post-mortem examination of brain histology), that 
become apparent when there is already irreversible brain damage and the disease-modifying 
potential is lost (Garcia-Alloza et al., 2009). Likewise, the inclusion on clinical trials of 
patients in different stages of the disease, or even misdiagnosed, not only limits the study 
power, adding the need of greater number of participants and time of follow-up, but also 
could compromise the evaluation of the drug efficacy.  
Taken together, the reasons presented above illustrate the critical need of diagnosing 
individuals at the preclinical or asymptomatic phase and enroll them in clinical trials in order 
to identify therapies that could prevent or delay the decline in brain functions (Fagan et al., 
2012). It is also important an improved knowledge of disease mechanisms that could unravel 
new therapeutic targets and provide a better assessment of disease progression and clinical 
effects of promising new drugs. Biomarkers are critical tools for those and several other 
purposes, and its urgent requirement has been underlined on a recent publication of the US 
FDA’s Critical Path Opportunities Report (National Institute of Mental Health, 2011). 
In this review we focus on a few neurodegenerative disorders, namely Alzheimer’s and 
Parkinson’s disease, ALS and two polyglutamine diseases, Huntington’s and Machado Joseph’s. 
For each one we detail biochemical markers in the cerebrospinal fluid (CSF). The CSF is in 
direct contact with the CNS, and this close proximity with the affected areas by 
neurodegenerative diseases make it an optimal fluid for measurements, able to reflect the 
brain metabolism and biochemical state in health and pathology (Zetterberg et al., 2006).  
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2. Biomarkers 
 
The identification of specific biomarkers for neurodegenerative diseases is one of the 
main goals of the current clinical research mainly because they are critical for differential 
diagnosis between related and clinically similar pathologies, for assessment of disease-
modifying drugs for which is imperative an early diagnosis and to follow disease progression 
that allows a better patients enrolment and objective evaluation of drug effects in clinical 
trials (Morgan et al., 2010). 
 
2.1. Definitions 
According to the Biomarkers Definitions Working Group, a biomarker is a 
“characteristic that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group, 2010). Frequently, they are classified in prognostic, 
diagnostic or theragnostic biomarkers, based on what they measure.  
A surrogate marker is defined as a validated substitute of a clinical outcome and is 
expected to predict the effect of therapy (Katz, 2004). Surrogate endpoints are a subgroup 
of biomarkers, but given the restrictive requirements for a biomarker to be considered a 
surrogate marker, only a few achieve this status (Prentice, 1989). 
 
2.2. Characteristics of an ideal biomarker 
 There are several requirements for a parameter to be considered a biomarker, namely 
validity, performance and generalizability (Constantinescu et al., 2013). In order to meet the 
first requirement, there must be a solid correlation between the biomarker and the disease 
for which it is suggested. The biomarker performance answers questions related to reliability 
and reproducibility, as well as to the ability to differentiate between individuals affected and 
non-affected. It also relates with some characteristics like safety, tolerability, simplicity and 
low cost. Finally, the generalizability reports to the capability of maintaining a good 
performance not only in different patients with different age, gender, disease stage and other 
variables, but also in different studies performed by different groups and research or medical 
centers (Brooks et al., 2003; Marek et al., 2008). 
 In other words, an ideal biomarker should be sensitive, specific, reproducible, closely 
related with disease pathological mechanisms, easy to measure and with reduced costs, 
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noninvasive and thoroughly validated. Its sensitivity and specificity should be greater than 
80% (van Dijk KD et al., 2010). 
 
2.3. The need for biomarkers in neurodegenerative disorders 
Biomarkers can be useful for diagnostic, prognostic or drug development and for most of 
neurodegenerative diseases they are equally important for all of these applications, with the 
potential for solving many limiting issues. In fact, there are no disease modifying-therapies for 
these disorders so far and the lack of biomarkers is presented as one of the main reasons 
for that absence (Olanow et al., 2008). As we pointed before, most of the patients are 
identified only when they present clinical symptoms, and the degeneration has already 
progressed so far that it may be difficult for any therapy to be effective except a 
symptomatic one. Also, even if patients could be identified sooner, the time frame and the 
number of patients in clinical trials required to see a real clinical outcome would present 
serious limitations, besides the difficulties presented by the lack of a reliable assessment of 
that outcome (Ravina et al., 2003, Kieburtz et al., 2007).  
In a more detailed way, the problems that could be solved by finding appropriate 
biomarkers include achievement of a differential diagnostic, establishment of time of disease 
onset and progression and assessment of therapy effects (Constantinescu et al., 2013). In 
neurodegenerative disorders, a differential diagnostic could be difficult during early phases 
and is not uncommon to mix patients with different diseases, which may lead to negative or 
inconclusive results in clinical trials. A diagnostic biomarker that could point to the right 
diagnosis would decrease the cost, time and effort and increase the probability of success. It 
could also help stratifying patients with different responses to a given therapy (Marek et al., 
2008). As important as a correct diagnosis is an early one, since these diseases are 
asymptomatic for several years and even efficacious therapies may be powerless if given 
when neuron loss has gone too far. A biomarker able to detect the disease onset or in early 
phases may allow those therapies to be effective, stopping or delaying the progression of 
disease (Stern et al., 2012). Likewise, there is still no valid way to assess the impact and 
benefit degree of a therapeutic intervention. Theragnostic biomarkers, i.e. those able to 
identify and monitor the effect of drugs, could benefit not only therapy research but also 
have the potential to be used as surrogate markers in clinical trials. Furthermore, biomarkers 
could also be useful in deciphering pathological and etiological mechanisms of such complex 
diseases, a knowledge helpful for design and research of new therapeutic strategies 
(Constantinescu et al., 2013). 
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2.4. Biomarker modalities used in neurodegenerative diseases 
For neurodegenerative diseases, as for many others, the research for biomarkers, mainly 
for diagnostic and prognostic purposes, could be done in body fluids or by means of imaging 
techniques, in addition to several clinical markers already used in clinical practice (Marek et 
al., 2008). 
Many different imaging modalities are becoming widely used, particularly those based on 
magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), 
ultra-sounds and positron emission tomography (PET). This last technique is often used with 
different marker compounds like fluorodeoxyglucose (FDG) or amyloid ligands such as 
Pittsburgh compound B (PIB) and could allow correlations with biochemical markers 
concentration (Nordberg et al., 2009). One example is the inverse correlation between CSF 
concentrations of Aβ42 and PIB binding, both pointing to brain amyloid burden (Fagan et al., 
2009). Thus, it is likely helpful combining different biomarker modalities in order to increase 
diagnostic or prognostic accuracy (Vemuri et al., 2009). 
Different body fluids or tissues (e.g., CSF, blood, urine, and brain tissue) could be 
analyzed for discovery of biochemical markers, either genetic or proteic. This research could 
be done in a targeted way, investigating defined compounds, usually related with the disease 
pathophysiology, or could be untargeted, where the researchers investigate a large amount 
of components in patients and controls samples. Nowadays, this kind of search is possible 
due to several “omics” techniques, such as genomics (genome analysis), transcriptomics 
(transcriptome or gene expression analysis), proteomics (proteome analysis) and 
metabolomics (metabolome or small-molecule metabolites analysis) (Constantinescu et al. 
2013). 
Until now, the CSF markers are probably the best studied, presenting the most 
promising and reproducible results. While blood or urine-based assays are desirable given its 
safety, tolerability and simplicity, the results are not easily reproducible or consistent. This 
review will focus on CSF biomarkers in neurodegenerative disorders. Blood or other body 
fluid markers are reviewd elsewhere (Kolarcik et al., 2006; Sheta et al., 2006; Goldknopf et al., 
2009; Borovecki et al., 2010;  Thambisetty et al., 2010; Noelker et al., 2011), as well as 
neuroimaging markers (Bohanna et al., 2008; Mori et al., 2012; Rocha et al., 2012; Seibyl et al., 
2012; Weiner et al., 2012). 
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2.5. Stages of fluid  biomarkers development 
Generally, there are several stages in the discovery and development of new biomarkers 
(Rifai et al., 2006). It usually begins with a discovery phase, where an initial association is 
made. A small number of well-characterized samples could be compared in an unbiased way 
for a high number of analytes or for a specific parameter that is already suggested as a 
possible biomarker. The candidates are then confirmed or discarded in the qualification 
phase, after being studied by other analytical methods and possibly in different samples. The 
specificity of putative biomarkers is then examined in the verification phase. In this stage a 
large number of samples are analyzed and assessed for variation caused by genetic, biological 
and environmental factors. Finally the validation phase takes place, done only on the few 
candidates that performed well in the previous phases (Figure 1). Several thousands of 
samples are then investigated for biomarker sensitivity, specificity and reproducibility, as well 
as its standardization potential, before further evaluation and use in clinical routine 
(Kroksveen  at al., 2011). 
 
 
 
Figure 1. Stages in the development of novel biomarker candidates.  
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2.6. Challenges in biomarker discovery for neurodegeneration 
There are several obstacles to the development of biomarkers for neurodegenerative 
diseases (Fagan et al., 2010; Constantinescu et al., 2013). First, the complexity of such 
disorders, with heterogeneous clinical presentations and progression, as well as a multitude 
of potential etiologies, raises the hypothesis that a single biomarker could not be sufficient to 
cover all the aspects of disease. Second, the patient classification is subjective, since criteria 
for clinical diagnostic may have different interpretations and change over time, lacking 
accuracy, particularly at early stages of the disease. Confirming the diagnosis and at the same 
time the value of a biomarker, is almost unrealistic, since it requires a postmortem brain 
examination and these diseases progress at a slow rate. Third, due to the difficulties 
explained above for identifying patients in preclinical stages, it is highly probable that some of 
them may be included in control groups, thus affecting the results of biomarkers 
performance. Fourth, the patient sample size is usually limited and not corrected for the 
impact of variables such as age, gender, and APOE genotype, which restrict the 
generalizability of results. Fifth, biochemical markers concentrations vary considerably 
between studies, probably due to analytical factors related with sample collection and 
handling, or differences in protocols and kits used for measurements (Bjerke et al., 2010; 
Mattsson et al., 2010), limiting the reproducibility and the direct comparison of results and 
raising the need for methods harmonization. In order to overcome these issues, there are 
some joint programs involving different countries and research centers, with the common 
goal of finding causes, cures and developing accurate biomarkers. One of these initiatives is 
the EU Joint Programme for Neurodegenerative Disease Research (JNPD), already involving 
21 countries and having one programme in particular dedicated to biomarkers information 
and harmonization, the BIOMARKAPD. This program offers details about standardization in 
biomarker measurements, samples collection and results interpretation (EU JPND Research, 
2011). 
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3. Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, affecting 
approximately 10.6 million people in USA and Europe and this number is estimated to rise to 
15.4 million in 2030 (Alzheimer’s Association, 2011). In 2011, the cost of care in the USA 
alone was almost US$183 billion and the projected costs for 2050 are over US$1.1 trillion if 
an effective disease-modifying therapy remains elusive (Brookmeyer et al., 2011).  
 Although phenotypically indistinguishable, the disease is generally classified according to 
the age of onset and presence of genetic heterogeneity, in late and early onset, typically 
corresponding to sporadic and familial forms, respectively. The vast majority of cases (more 
than 90%) are sporadic, diagnosed after 65 years of age, with no known genetic cause 
associated (Tandon et al., 2000).  
  
 3.1. Clinical presentation and diagnosis 
Most frequently, the first symptom in patients suffering from AD is the difficulty to 
remember new information, caused by neuronal loss in the brain regions responsible for 
memory, specifically the cerebral cortex and hippocampus (Selkoe, 2001). As the brain 
damage progress patients could experience more severe memory loss, disorientation, 
inability to perform simple daily tasks, confusion, alterations of language and learning, 
decreased judgment, changes in mood and personality and an extensive decline in general 
cognitive function (Tanzi et al., 2005; Alzheimer’s Association, 2013).  
 The definitive diagnosis is only possible postmortem, by a histological brain analysis. The 
clinical ante-mortem diagnosis is currently based on the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) or on criteria from the National Institute of 
Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) (McKhann  et al., 1984). Some of the principles in 
these documents include the development of memory impairment and one or more 
cognitive disturbances, which should exhibit gradual onset and cause impairment in daily 
living. However, these symptoms are very similar to other causes of dementia and they 
should be excluded, when possible, by means of medical and family history, physical and 
neurologic evaluation, and laboratory and neuroimaging tests (Hooper et al., 2008). Despite 
all these efforts, the diagnostic success rate is still very low, mainly at early stages, where 
symptoms are still subtle and do not interfere with daily activities, meeting the criteria for 
mild cognitive impairment (MCI) (Peterson et al., 1999). These patients show deficits on 
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cognitive tests when compared with age-matched controls, and studies suggest that it could 
be a stage between normal aging and dementia, frequently seen as a prodromal phase of AD 
(Grundman et al., 2004). Actually, the risk for patients with MCI to develop AD almost 
tripled compared to healthy controls, during a follow-up period of 5 years, but since MCI is a 
heterogeneous disorder, it may also progress to other dementias or only to the cognitive 
decline seen in normal aging (Rosén et al., 2013).  
 More recently, in face of the difficulties described above and the advances in imaging 
techniques (PET scan with Pittsburgh compound) and the validation of some core 
biomarkers (amyloid beta and tau protein) in CSF, the National Institute on Aging and 
Alzheimer’s Association workgroups have recommended the inclusion of these techniques 
and parameters on diagnostic guidelines (Albert et al., 2011; McKhann et al., 2011). 
 
 3.2. Pathological features 
The fundamental brain pathology in Alzheimer’s disease is characterized by extracellular 
senile plaques and intracellular neurofibrillary tangles. The amyloid or senile plaques are 
dense, mostly insoluble deposits of β-amyloid (Aβ) peptide outside neurons. These peptides 
are generated from two consecutive proteolytic cleavages of a larger protein called amyloid 
precursor protein (APP) by two enzymes: β-secretase (BACE-1 for β-site APP cleaving 
enzyme) and -secretase. The neurofibrillary tangles are insoluble twisted fibers of 
hyperphosphorilated tau protein that build up inside the nerve cell (Pastorino et al., 2006). 
According to the amyloid cascade theory, the deposition of Aβ is believed to be one of the 
central events in AD pathogenesis, which is also supported by familial cases of the disease 
caused by mutations in this peptide precursor or in the enzymes responsible for its cleavage. 
The Aβ peptide (particularly the isoform with 42 amino acids, Aβ42) seems to have an 
initiating role for other pathological features, namely astrocyte and glial activation that in 
turn leads to production of inflammatory mediators. The neuroinflammation and oxidative 
stress are responsible for the activation of several kinases and phosphatases, involved in tau 
hyperphosphorylation and consequent development of neurofibrillary tangles. The 
degenerative process spreads across neurons, disrupting axonal transport, damaging 
synapses and depleting neurotransmitters (particularly cholinergic), finally culminating in 
neuronal cell death, the ultimate responsible for dementia (Hardy, 2002). 
Notwithstanding the role of Aβ for the neurodegenerative process, several studies report 
a strong correlation between tangles and severity of dementia, but not for levels of amyloid 
peptides or senile plaques (Bierer et al., 1995; Nagy et al., 1995). 
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  3.3. Most promising biomarkers for AD in CSF  
Reflecting their role in Alzheimer’s disease pathogenesis, the most useful biomarkers so 
far are levels of Aβ42, total and hyperphosphorilated tau protein (t-Tau and p-Tau, 
respectively) and their ratios. These proteins in the cerebrospinal fluid are the first validated 
and well established biomarkers of neurodegenerative diseases, and have been extensively 
studied by several groups and researchers (Fagan et al., 2012). Their findings are summarized 
in Table 1.  
 
Table 1. Validated CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
Markers related with pathophysiology  
Aβ42 Poorly understood 
↓ 37/32 Motter et al. 1995 
↓ 24/25 Ida et al. 1996 
↓ 20/34 Tamaoka et al. 1997 
 ↓ 82/60 Galasko et al. 1998 
↓ 93/143 Kanai et al. 1998 
↓ 55/34 Shoji et al., 1998 
↓ 53/21 Andreasen et al. 1999a 
↓ 16/15 Andreasen et al. 1999b 
↓ 150/100 Hulstaert et al. 1999 
↑ 80/24 Jensen et al. 1999 
↓ 23/13 Fukuyama et al. 2000 
↓ 24/19 Kanemaru et al. 2000 
↓ 36/29 Mehta et al. 2000 
↓ 14/20 Otto et al. 2000 
↓ 75/35 Riemenschneider et al. 2000 
↓ 60/32 Sjogren et al. 2000 
↓ 39/12 Vanderstichele et al. 2000 
↓ 163/18 Andreasen et al. 2001 
↓ 38/47 Kapaki et al. 2001 
↓ 19/10 Montine et al. 2001 
↓ 27/70 Rösler et al. 2001 
↓ 32/10 Csernansky et al. 2002 
↓ 20/20 Mulder et al. 2002 
↓ 73/27 Nagga et al. 2002 
↓ 19/17 Sjögren et al. 2002 
↓ 44/32 Andreasen et al. 2003 
↓ 106/69 Clark et al. 2003 
↓ 33/46 Gómez-Tortosa et al. 2003 
Aβ42 Poorly understood 
↓ 49/49 Kapaki et al. 2003 
↓ 27/35 Skoog et al. 2003 
↓ 131/72 Sunderland et al. 2003 
↓ 145/10 Hampel et al. 2004b 
↓ 22/35 Lewczuk et al. 2004 
↓ 17/13 Grossman et al. 2005 
↓ 46/78 Herukka et al. 2005 
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Table 1 (continued). Validated CSF biomarkers for Alzheimer’s disease  
Biomarker Function Findings n (AD/control) References 
Aβ42 Poorly understood 
↓ 39/35 Jia et al. 2005 
↓ 23/27 Blasko et al. 2006 
↓ 6/18 Fagan et al. 2006 
↓ 49/90 Fagan et al. 2007 
 ↓ 79/60 Herukka et al. 2007 
↓ 100/100 Engelborghs et al. 2008 
↓ 22/21 Brys et al. 2009 
↓ 35/29 Hansson et al. 2009 
↓ 30/30       Bjerke et al. 2011 
↓ 98/211 Tarawneh et al. 2011 
↓ 88/155 Lewczuk et al. 2012 
↓ 60/28 Parnetti et al. 2012 
↓ 61/40       Luo et al. 2013 
tTau  
Microtubule 
stabilization 
↑ 27/51 Vandermeeren et al. 1993 
↑ 70/115 Arai et al. 1995 
↑ 44/31 Blennow et al. 1995b 
↑ 19/18 Hock et al. 1995 
↑ 82/22 Jensen et al. 1995 
↑ 14/36 Mori et al. 1995 
↑ 37/32 Motter et al. 1995 
↑ 24/14 Munroe et al. 1995 
↑ 26/35 Skoog et al. 1995 
↑ 23/23 Tato et al. 1995 
↑ 71/110 Vigo-Pelfrey et al. 1995 
↑ 18/9 Blomberg et al. 1996 
↑ 22/19 Riemenschneider et al. 1996 
↑ 16/26 Rösler et al. 1996 
↑ 91/77 Arai et al. 1997a 
↑ 17/15 Arai et al. 1997b 
↑ 36/14 Galasko et al. 1997 
↑ 19/12 Golombowski et al. 1997 
↑ 43/18 Andreasen et al. 1998 
↑ 69/17 Arai et al. 1998 
↑ 82/60 Galasko et al. 1998 
↑ 93/143 Kanai et al. 1998 
↑ 40/36 Kurz et al. 1998 
↑ 29/23 Mecocci et al. 1998 
tTau  
Microtubule 
stabilization 
↑ 163/65 Nishimura et al. 1998 
↑ 55/34 Shoji et al. 1998 
↑ 81/33 Tapiola et al. 1998 
↑ 16/15 Andreasen et al. 1999b 
↑ 38/28 Buerger et al. 1999 
↑ 25/19 Hampel et al. 1999 
↑ 150/100 Hulstaert et al. 1999 
↑ 17/23 Green et al. 1999 
↑ 36/20 Ishiguro et al. 1999 
↑ 83/88 Molina et al. 1999 
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Table 1 (continued). Validated CSF biomarkers for Alzheimer’s disease  
Biomarker Function Findings n (AD/control) References 
tTau  Microtubule 
stabilization 
↑ 36/23 Morikawa et al. 1999 
↑ 34/25 Tarkowski et al. 1999 
↑ 35/16 Kahle et al. 2000 
↑ 24/19 Kanemaru et al. 2000 
↑ 60/32 Sjogren et al. 2000a 
↑ 42/18 Sjogren et al. 2000b 
↑ 163/18 Andreasen et al. 2001 
↑ 17/12 Hampel et al. 2001 
↑ 236/95 Itoh et al. 2001 
↑ 38/47 Kapaki et al. 2001 
↑ 19/10 Montine et al. 2001 
↑ 80/40 Parnetti et al. 2001 
↑ 27/70 Rösler et al. 2001 
↑ 60/17 Sjogren et al. 2001a 
↑ 47/12 Sjogren et al. 2001b 
↑ 32/10 Csernansky et al. 2002 
↑ 52/56 Hu et al. 2002b 
↑ 20/20 Mulder et al. 2002 
↑ 73/27 Nagga et al. 2002 
↑ 19/17 Sjögren et al. 2002 
↑ 366/181 Shoji et al. 2002 
↑ 44/32 Andreasen et al. 2003 
↑ 106/69 Clark et al. 2003 
↑ 33/46 Gómez-Tortosa et al. 2003 
↑ 49/49 Kapaki et al. 2003 
↑ 25/16 Schönknecht et al. 2003 
↑ 131/72 Sunderland et al. 2003 
 ↑ 145/10 Hampel et al. 2004b 
↑ 22/35 Lewczuk et al. 2004 
↑ 17/13 Grossman et al. 2005 
↑ 46/78 Herukka et al. 2005 
↑ 39/35 Jia et al. 2005 
↑ 23/27 Blasko et al. 2006 
↑ 49/90 Fagan et al. 2007 
pTau  Microtubule 
stabilization 
↑ 79/60 Herukka et al. 2007 
↑ 100/100 Engelborghs et al. 2008 
↑ 22/21 Brys et al. 2009 
↑ 55/130 van Eijk et al. 2010 
↑ 30/30       Bjerke et al. 2011 
↑ 98/211 Tarawneh et al. 2011 
↑ 60/28 Parnetti et al. 2012 
↑ 61/40       Luo et al. 2013 
↑ 44/31 Blennow et al. 1995b 
↑ 36/20 Ishiguro et al. 1999 
↑ 27/31 Kohnken et al. 2000 
↑ 17/12 Hampel et al. 2001 
↑ 236/95 Itoh et al. 2001 
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Table 1 (continued). Validated CSF biomarkers for Alzheimer’s disease  
Biomarker Function Findings n (AD/control) References 
pTau  Microtubule 
stabilization 
↑ 80/40 Parnetti et al. 2001 
↑ 60/17 Sjogren et al. 2001 
↑ 82/21 Buerger et al. 2002 
↑ 52/56 Hu et al. 2002b 
↑ 73/27 Nagga et al. 2002 
↑ 19/17 Sjögren et al. 2002 
↑ 44/32 Andreasen et al. 2003 
↑ 81/21 Buerger et al. 2003 
↑ 25/16 Schönknecht et al. 2003 
↑ 108/45 Hampel et al. 2004a 
↑ 17/13 Grossman et al. 2005 
↑ 46/78 Herukka et al. 2005 
↑ 39/35 Jia et al. 2005 
↑ 23/27 Blasko et al. 2006 
↑ 49/90 Fagan et al. 2007 
↑ 79/60 Herukka et al. 2007 
↑ 100/100 Engelborghs et al. 2008 
↑ 22/21 Brys et al. 2009 
↑ 30/30       Bjerke et al. 2011 
↑ 88/155 Lewczuk et al. 2012 
↑ 60/28 Parnetti et al. 2012 
↑ 61/40       Luo et al. 2013 
 
 
↑ increased; ↓ decreased; ↔ no significant alterations; Control refers to healthy subjects. 
Aβ42: Beta amyloid; t-Tau: Total tau protein; p-Tau: Phosphorylated tau protein. 
 
 In a general way, increased levels of tau protein and decreased levels of Aβ42 are found in 
CSF of AD patients, as compare to healthy, non-demented controls. Only one study 
reported a significant increase of Aβ42 in CSF of patients in early and mid-stages of AD, yet 
declining with disease progression (Jensen et al., 1999), which may be explained by 
methodological factors. Low levels of Aβ42 are associated with amyloid deposition in 
plaques (Fagan et al., 2006), while elevated tau levels, total or hyperphosphorilated, are 
expected as a result from tissue damage and the development of neurofibrillary tangles 
(Buerger et al., 2006).These markers not only have a sensitivity and specificity greater than 
80% for diagnosing AD, but are also able to identify the disease at early stages, namely in 
patients with mild cognitive impairment (MCI), predicting the development of Alzheimer’s 
(Riemenschneider et al., 2002; Herukka et al., 2005, Hansson et al., 2006; Hansson et al., 
2007; Herukka et al., 2007; Mattsson et al., 2012; Palmqvist et al., 2012; Parnetti  et al., 2012; 
Tabaraud et al., 2012). 
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 3.4. Recent candidate biomarkers in CSF 
Aiming an increase in diagnostic accuracy and reducing variability between studies, 
numerous other biomarker candidates are being pursued, that can identify mixed pathologies 
and additional processes involved in AD.  In Figure 2 are represented some of the most 
relevant complementary candidate markers, reflecting more general neurodegenerative 
mechanisms, like neuroinflammation and synaptic dysfunction and loss, as well as some 
others whose involvement in Alzheimer’s disease is not well understood so far (Fagan et al., 
2012).  
 
 
 
 
Figure 2. Schematic representation of the origin of CSF biomarkers in AD (Fagan et al., 2012). In 
addition to core biomarkers, some neuronal proteins as well as neurotrophic and growth factors, 
generally decline in AD, perhaps reflecting synapse and neuronal loss. On the other hand, 
neuroinflammatory mediators and products of oxidative damage are usually elevated.  (Molecules 
name abbreviations are detailed in Table 2).  
 
The most important findings for those markers are summarized in Table 2. Only potential 
biomarkers with at least one study reporting an increased or decreased value are presented. 
 
Table 2. Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
Markers related with axonal degeneration 
NfH Axonal structure 
protein 
↑ 52/66 Hu et al. 2002a 
↑ 109/58 Brettschneider et al. 2006d 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
NfH Axonal structure 
protein 
↑ 55/130 van Eijk et al. 2010 
↔ 68/24 Kester et al. 2012 
NfL Axonal structure 
protein 
↑ 42/18 Sjogren et al. 2000b 
↑ 52/66 Hu et al. 2002a 
↑ 20/25 Pijnenburg et al. 2007 
↑ 55/130 van Eijk et al. 2010 
↑ 30/30 Bjerke et al. 2011 
↔ 68/24 Kester et al. 2012 
TG Protein cross-linking ↑ 33/33 Bonelli et al. 2002 
sAPP Neurotrophic factor 
↓ 45/26 Peskind et al. 1997 
↔ 14/15 Hock et al. 1998 
↓ 13/13 Sennvik et al. 2000 
↑ 47/12 Sjögren et al. 2001b 
↓ 32/10 Csernansky et al. 2002 
↓ 25/16 Wu et al. 2011 
sAPPβ Neurite outgrowth 
↔ 13/13 Sennvik et al. 2000 
↔ 81/43 Olsson et al. 2003 
↑ 87/33 Zetterberg et al. 2008 
↑ 69/48 Lewczuk et al. 2010 
↓ 25/16 Wu et al. 2011 
↑ 88/155 Lewczuk et al. 2012 
↔ 75/65 Rosén et al. 2012 
↔ 43/44 Brinkmalm et al. 2013 
sAPPα Neurotrophic factor 
↓ 13/13 Sennvik et al. 2000 
↓ 33/22 Colciaghi et al. 2002 
↔ 81/43 Olsson et al. 2003 
↑ 87/33 Zetterberg et al. 2008 
↑ 69/48 Lewczuk et al. 2010 
↓ 25/16 Wu et al. 2011 
↑ 88/155 Lewczuk et al. 2012 
↔ 75/65 Rosén et al. 2012 
↔ 43/44 Brinkmalm et al. 2013 
GFAP Cytoskeletal protein 
↑ 37/39 Wallin et al. 1996 
↑ 27/26 Fukuyama et al. 2001 
↑ 18/14 Jesse et al. 2009 
↑ 55/130 van Eijk et al. 2010 
Markers related with inflammation and immune response 
IL-1 beta Immune response 
↔ 13/15 Martinez et al. 1993b 
↔ 40/42 Pirttila et al. 1994 
↑ 11/12 Blum-Degen et al.1995 
↔ 8/9 Lanzrein et al. 1998 
↔ 42/20 Engelborghs et al. 1999 
↔ 34/25 Tarkowski et al. 1999 
↔ 10/10 Martínez et al. 2000 
↔ 33/46 Gómez-Tortosa et al. 
2003 ↔ 20/21 Richartz et al. 2005 
sIL-1R Immune response ↑ 12/13 Garlind et al. 1999 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
IL-6 Immune response 
↑ 11/12 Blum-Degen et al.1995 
↓ 12/7 Yamada et al. 1995 
↔ 25/19 Hampel et al. 1997 
↔ 17/18 März et al. 1997 
↔ 8/9 Lanzrein et al. 1998 
↔ 42/20 Engelborghs et al. 1999 
↔ 12/13 Garlind et al. 1999 
↔ 25/19 Hampel et al. 1999 
↔ 34/25 Tarkowski et al. 1999 
↑ 10/10 Martínez et al. 2000 
↑ 27/70 Rösler et al. 2001 
↑ 33/46 Gómez-Tortosa et al. 
2003 ↑ 39/35 Jia et al. 2005 
↔ 20/21 Richartz et al. 2005 
IL-6 Immune response 
↔ 43/30 Galimberti et al. 2008 
↔ 31/19 Popp et al. 2009 
sIL-6R Immune response 
↔ 17/18 März et al. 1997 
↓ 41/41 Hampel et al. 1998 
↓ 25/19 Hampel et al. 1999 
↑ 58/25 Bagli et al. 2003 
Gp130 Cytokine receptor 
↔ 17/18 März et al. 1997 
↓ 25/19 Hampel et al. 1999 
IL-7 Immune response 
↓ 66/33 Hu et al. 2010 
↓ 91/242 Craig-Schapiro et al. 
2011 IL-11 Immune response ↑ 43/30 Galimberti et al. 2008 
TRAIL-R3 Immune response 
↑ 66/33 Hu et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 MIF 
Inflammatory 
response 
↑ 31/19 Popp et al. 2009 
↑ 91/242 Craig-Schapiro et al. 
2011 
Isoprostanes 
Inflammatory 
mediators 
↑ 11/11 Montine et al. 1998 
↑ 4/3 Roberts et al. 1998 
↑ 7/7 Montine et al. 1999b 
↑ 14/10 Praticò et al. 2000 
Isoprostanes 
Inflammatory 
mediators 
↑ 19/10 Montine et al. 2001 
↑ 28/18 Praticò et al. 2002 
↑ 17/13 Grossman et al. 2005 
↑ 6/11 de Leon et al. 2007 
↑ 22/21 Brys et al. 2009 
↔ 68/24 Kester et al. 2012 
↑ 63/20 Duits et al. 2013 
PG 
Inflammatory 
mediators 
↑ 7/7 Montine et al. 1999b 
↓ 7/7 Puchades et al. 2003 
↓ 11/8 Korolainen et al. 2007 
Pentraxin Immune response 
↑ 10/10 Abdi et al. 2006 
↑ 52/44 Finehout et al. 2007 
↑ 3/3 Yin et al. 2009 
     
  
22 
     
Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
C3 Inflammatory 
response 
↓ 82/21 Buerger et al. 2002 
↔ 9/9 Finehout et al. 2005 
↑ 52/44 Finehout et al. 2007 
↑ 113/28 Simonsen et al. 2007 
↑ 125/100 Simonsen et al. 2008 
↑ 66/33 Hu et al. 2010 
↑ 50/137 Wang et al. 2011 
C4 Inflammatory 
response 
↑ 9/9 Finehout et al. 2005 
↑ 10/10 Abdi et al. 2006 
↑ 113/28 Simonsen et al. 2007 
↓ 3/3 Yin et al. 2009 
↑ 24/24 Perrin et al. 2011 
Factor H Inflammatory 
response 
↑ 50/137 Wang et al. 2011 
MCP-1 Inflammatory 
response 
↑ 23/27 Blasko et al. 2006 
↔ 11/13 Choi et al. 2008 
↑ 91/242 Craig-Schapiro et al. 
2011 ↑ 47/30 Westin et al. 2012 
TNF-α Immune response 
↔ 8/9 Lanzrein et al. 1998 
↔ 42/20 Engelborghs et al. 1999 
↔ 12/13 Garlind et al. 1999 
↑ 34/25 Tarkowski et al. 1999 
↑ 52/25 Tarkowski et al. 2000 
↑ 39/35 Jia et al. 2005 
↓ 20/21 Richartz et al. 2005 
↔ 23/27 Blasko et al. 2006 
↔ 31/19 Popp et al. 2009 
sTNFR Immune response 
↔ 8/9 Lanzrein et al. 1998 
↔ 34/25 Tarkowski et al. 1999 
↔ 20/21 Richartz et al. 2005 
↑ 137/30 Buchhave et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 sTNFR Immune response ↑ 32/27 Jiang et al. 2011 
Neopterin Immune response ↔ 42/20 Engelborghs et al. 1999 
↔ 24/16 Milstien et al. 1994 
Markers related with neuroprotection 
GAP-43 Axonal growth ↑ 47/12 Sjogren et al. 2001b 
TGFβ-1 Growth factor 
↑ 20/27 Tarkowski et al. 2002 
↑ 20/20 Zetterberg et al. 2004 
↔ 23/27 Blasko et al. 2006 
↑ 30/25 Rota et al. 2006 
PEDF Neurotrophic factor 
↑ 43/43 Castaño et al. 2006 
↔ 47/43 Roher et al. 2009 
↔ 27/27 Abraham et al. 2011 
VEGF Angiogenic factor 
↑ 20/27 Tarkowski et al. 2002 
↔ 23/27 Blasko et al. 2006 
↓ 91/242 Craig-Schapiro et al. 
2011 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
VEGF Angiogenic factor ↓ 69/92 Guo et al. 2013 
VGF Growth factor 
↓ 9/10 Carrette et al. 2003 
↓ 113/28 Simonsen et al. 2007 
↓ 125/100 Simonsen et al. 2008 
↓ 34/17 Jahn et al. 2011 
↓ 24/24 Perrin et al. 2011 
Clusterin 
 
Chaperone 
↓ 7/7 Puchades et al. 2003 
↑ 12/12 Sihlbom et al. 2008 
↔ 66/33 Hu et al. 2010 
 ↔ 91/242 Craig-Schapiro et al. 
2011 Clusterin Chaperone ↔ 24/24 Perrin et al. 2011 
Cystatin C 
Cysteine protease 
inhibitor 
↑ 9/10 Carrette et al. 2003 
↑ 113/28 Simonsen et al. 2007 
↑ 125/100 Simonsen et al. 2008 
↓ 35/29 Hansson et al. 2009 
↓ 91/242 Craig-Schapiro et al. 
2011 ↓ 24/24 Perrin et al. 2011 
↔ 101/28 Sundelöf et al. 2012 
β2microglobulin HLA complex 
↑ 13/15 Martinez et al. 1993b 
↑ 15/12 Davidsson et al. 2002 
↑ 9/10 Carrette et al. 2003 
↓ 7/7 Puchades et al. 2003 
↑ 10/10 Abdi et al. 2006 
↑ 113/28 Simonsen et al. 2007 
↓ 125/100 Simonsen et al. 2008 
↓ 24/24 Perrin et al. 2011 
Markers related with oxidative stress 
HNE Lipid peroxidation ↑ 19/13 Lovell et al. 1997 
↑ 8/6 Selley et al. 2002 
8-OHdG 
DNA oxidative 
damage 
↑ 18/7 Lovell et al. 2001 
↑ 18/15 Abe et al. 2005 
↑ 30/30 Isobe et al. 2010 
3-NT Protein nitration ↑ 25/24 Tohgi et al. 1999a 
↑ 32/18 Ahmed et al. 2005 
SOD1 Detoxification  ↓ 22/41 Boll et al. 2008 
Nitrate 
NO 
biotransformation 
↓ 13/20 Kuiper et al. 1994b 
↔ 24/16 Milstien et al. 1994 
↔ 36/36 Navarro et al. 1996 
↑ 22/41 Boll et al. 2008 
Haptoglobin Hemoglobin binding 
↑ 10/10 Abdi et al. 2006 
↓ 30/30 Jung et al. 2008 
↓ 27/27 Abraham et al. 2011 
Transferrin Iron binding 
↑ 14/25 Chapel et al. 1984 
↔ 17/11 Loeffler et al. 1994 
Ceruloplasmin Copper transport 
↑ 17/11 Loeffler et al. 1994 
↔ 10/10 Abdi et al. 2006 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
Others 
α-Synuclein Poorly understood 
↓ 66/55 Ohrfelt et al. 2009 
↔ 26/24 Wennstrom et al. 2012 
↑ 200/200 Korff et al. 2013 
↓ 61/40 Luo et al. 2013 
hFABP Fatty acid metabolism 
↑ 32/25 Chiasserini et al. 2010 
↑ 66/33 Hu et al. 2010 
↑ 30/30 Bjerke et al. 2011 
hFABP Fatty acid metabolism ↑ 91/242 Craig-Schapiro et al. 
2011 ↑ 69/92 Guo et al. 2013 
MMP-2 Protein degradation 
↓ 5/15 Mlekusch et al. 1999 
↔ 31/41 Lorenzl et al. 2003 
↓ 14/14 Horstmann et al. 2010 
↔ 30/30 Bjerke et al. 2011 
MMP-3 Protein degradation 
↓ 5/15 Mlekusch et al. 1999 
↑ 14/14 Horstmann et al. 2010 
↑ 38/34 Stomrud et al. 2010 
↔ 30/30 Bjerke et al. 2011 
MMP-9 Protein degradation 
↑ 31/41 Lorenzl et al. 2003 
↔ 30/30 Adair et al. 2004 
↑ 38/34 Stomrud et al. 2010 
↔ 30/30 Bjerke et al. 2011 
MMP-10 Protein degradation ↑ 91/242 Craig-Schapiro et al. 
2011 ↑ 30/30 Bjerke et al. 2011 
PP Pancreatic regulation 
↑ 66/33 Hu et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 Resistin Secretory factor ↑ 66/33 Hu et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 
TIMP-1 MMP-1 inhibitor 
↑ 31/41 Lorenzl et al. 2003 
↓ 38/34 Stomrud et al. 2010 
↔ 30/30 Bjerke et al. 2011 
TIMP-2 MMP-2 inhibitor ↑ 31/41 Lorenzl et al. 2003 
↔ 30/30 Bjerke et al. 2011 
Glutamate Excitotoxicity 
↔ 11/23 Smith et al. 1985 
↓ 22/11 Basun et al. 1990 
↑ 10/10 Pomara et al. 1992 
↓ 13/15 Martinez et al. 1993a 
↑ 37/32 Jiménez-Jiménez et al. 
1998b 
Transthyretin Thyroid hormone 
binding 
↓ 40/109 Serot et al. 1997 
↓ 20/10 Merched et al. 1998 
↑ 15/12 Davidsson et al. 2002 
↓ 7/7 Puchades et al. 2003 
↑ 10/10 Abdi et al. 2006 
↓ 43/43 Castaño et al. 2006 
↑ 52/44 Finehout et al. 2007 
↓ 11/8 Korolainen et al. 2007 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
Transthyretin Thyroid hormone 
binding 
↓ 23/19 Gloeckner et al. 2008 
↓ 35/29 Hansson et al. 2009 
↔ 47/43 Roher et al. 2009 
Transthyretin Thyroid hormone 
binding 
↔ 59/13 Schultz et al. 2010 
↓ 24/24 Perrin et al. 2011 
Gelsolin Actin binding protein ↓ 39/55 Hu et al. 2007 
↓ 24/24 Perrin et al. 2011 
IGF-1 Cell proliferation ↑ 41/41 Salehi et al. 2008 
↔ 32/20 Johansson et al. 2013 
IGFBP IGF binding protein 
↑ 41/41 Salehi et al. 2008 
↑ 91/242 Craig-Schapiro et al. 
2011 ↔ 32/20 Johansson et al. 2013 
α1-Antitrypsin Protease inhibitor 
↔ 5/7 Delamarche et al. 1991 
↓ 7/7 Puchades et al. 2003 
↑ 10/10 Abdi et al. 2006 
↑ 52/44 Finehout et al. 2007 
↑ 258/37 Nielsen et al. 2007 
↑ 60/37 Ewers et al. 2008 
↓ 12/12 Sihlbom et al. 2008 
↓ 35/29 Hansson et al. 2009 
↑ 3/3 Yin et al. 2009 
↑ 91/242 Craig-Schapiro et al. 
2011 
ACT Protease inhibitor 
↑ 15/26 Matsubara et al. 1990 
↔ 5/7 Delamarche et al. 1991 
↔ 24/25 Furby et al. 1991 
↔ 40/42 Pirttila et al. 1994 
↑ 66/54 Harigaya et al. 1995 
↑ 33/11 Licastro et al. 1995 
↔ 8/9 Lanzrein et al. 1998 
↑ 34/16 DeKosky et al. 2003 
↑ 39/55 Hu et al. 2007 
↑ 258/37 Nielsen et al. 2007 
↓ 125/100 Simonsen et al. 2008 
↑ 24/24 Perrin et al. 2011 
Neuroserpin Protease inhibitor ↑ 258/37 Nielsen et al. 2007 
α2Macroglobulin Antiprotease ↑ 66/33 Hu et al. 2010 
↑ 24/24 Perrin et al. 2011 
ZAG Lipid mobilization ↑ 39/55 Hu et al. 2007 
↓ 47/43 Roher et al. 2009 
Tetranectin Plasminogen binding ↑ 6/7 Wang et al. 2010 
↓ 33/20 Vafadar et al. 2012 
Fibrinogen Coagulation cascade 
↑ 10/10 Abdi et al. 2006 
↑ 52/44 Finehout et al. 2007 
↑ 91/242 Craig-Schapiro et al. 
2011 ↑ 33/20 Vafadar et al. 2012 
ATIII Coagulation cascade ↑ 39/55 Hu et al. 2007 
CNDP1 Carnosine hydrolysis ↓ 39/55 Hu et al. 2007 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
CNDP1 Carnosine hydrolysis ↑ 3/3 Yin et al. 2009 
↓ 24/24 Perrin et al. 2011 
Osteopontin 
Stress and 
inflammation 
↑ 67/69 Comi et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 ↑ 35/20 Sun et al. 2013 
Copper Micronutrient  
↑ 24/28 Basun et al. 1991 
↔ 26/28 Molina et al. 1998 
↔ 22/41 Boll et al. 2008 
↔ 173/54 Gerhardsson et al. 2008 
↔ 116/129 Bucossi et al. 2011 
↑ 21/15 Hozumi et al. 2011 
Orexin Neurotransmitter 
↑ 26/24 Wennstrom et al. 2012 
↓ 24/25 Fronczek et al. 2012 
↑ 33/33 Schmidt et al. 2013 
HVA Dopamine metabolite 
↓ 15/19 Bareggi et al. 1982 
↔ 11/32 Wood et al. 1982 
↑ 10/15 Zubenko et al. 1986 
↓ 22/32 Kawakatsu et al. 1990 
HVA Dopamine metabolite 
↔ 60/12 Molchan et al. 1991 
↓ 123/57 Blennow et al. 1992 
↑ 27/34 Hartikainen et al. 1992 
↓ 15/14 Parnetti et al. 1992 
↓ 60/31 Sjogren et al. 1998 
5HIAA Serotonin metabolite 
↔ 15/19 Bareggi et al. 1982 
↔ 11/32 Wood et al. 1982 
↓ 22/32 Kawakatsu et al. 1990 
↔ 60/12 Molchan et al. 1991 
↓ 123/57 Blennow et al. 1992 
↑ 27/34 Hartikainen et al. 1992 
↓ 15/14 Parnetti et al. 1992 
↓ 60/31 Sjogren et al. 1998 
MHPG Norepinephrine 
metabolite 
↔ 11/32 Wood et al. 1982 
↔ 60/12 Molchan et al. 1991 
↔ 123/57 Blennow et al. 1992 
↔ 27/34 Hartikainen et al. 1992 
↔ 15/14 Parnetti et al. 1992 
↔ 60/31 Sjogren et al. 1998 
↓ 79/51 Czech et al. 2012 
AChE Serine protease 
↔ 11/32 Wood et al. 1982 
↓ 7/32 Nakano et al. 1986 
↔ 10/15 Zubenko et al. 1986 
↓ 52/20 Kumar et al. 1989 
↓ 17/17 Sirvio et al. 1989 
↓ 22/32 Kawakatsu et al. 1990 
↓ 168/48 Reinikainen et al. 1990 
AChE Serine protease ↔ 27/34 Hartikainen et al. 1992 
↔ 22/78 Marksteiner et al. 2008 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
ACE Blood pressure 
regulation 
↓ 13/28 Zubenko et al. 1985 
↓ 10/15 Zubenko et al. 1986 
↓ 101/19 Miners et al. 2009 
BACE1 Aspartic protease 
↑ 5/5 Holsinger et al. 2004 
↑ 21/21 Holsinger et al. 2006 
↑ 67/69 Zhong et al. 2007 
↑ 60/37 Ewers et al. 2008 
↑ 87/33 Zetterberg et al. 2008 
↑ 17/12 Mulder et al. 2010 
↑ 30/19 Ewers et al. 2011 
↔ 25/16 Wu et al. 2011 
↔ 75/65 Rosén et al. 2012 
TACE Metalloprotease ↑ 32/27 Jiang et al. 2011 
Cathepsin D Aspartic protease ↓ 43/43 Castaño et al. 2006 
Hemopexin Heme binding ↑ 43/43 Castaño et al. 2006 
Somatostatin Neuropeptide 
↓ 11/32 Wood et al. 1982 
↓ 35/26 Francis et al. 1984 
↓ 10/21 Serby et al. 1984 
↓ 10/9 Raskind et al. 1986 
↓ 75/19 Reinikainen et al. 1987 
↓ 12/15 Sunderland et al. 1987 
↓ 25/8 Davis et al. 1988 
↓ 168/48 Reinikainen et al. 1990 
↓ 60/12 Molchan et al. 1991 
↓ 27/34 Hartikainen et al. 1992 
↓ 13/15 Martinez et al. 1993b 
↓ 49/13 Molchan et al. 1993 
↓ 36/40 Heilig et al. 1995 
Cg Neuroendocrine 
secretion 
↔ 29/9 Blennow et al. 1995a 
↓ 10/10 Abdi et al. 2006 
↓ 39/55 Hu et al. 2007 
↓ 113/28 Simonsen et al. 2007 
↑ 66/33 Hu et al. 2010 
↑ 91/242 Craig-Schapiro et al. 
2011 ↓ 24/24 Perrin et al. 2011 
Secretogranin 
Neuroendocrine 
secretion 
↓ 10/10 Abdi et al. 2006 
↓ 39/55 Hu et al. 2007 
↓ 24/24 Perrin et al. 2011 
VSNL1 Calcium sensor 
protein 
↑ 98/211 Tarawneh et al. 2011 
↑ 61/40 Luo et al. 2013 
ApoAI Lipid metabolism 
↓ 15/12 Davidsson et al. 2002 
↓ 7/7 Puchades et al. 2003 
↓ 
↓ 
43/43 Castaño et al. 2006 
↓ 47/43 Roher et al. 2009 
ApoAII Lipid metabolism ↑ 10/10 Abdi et al. 2006 
ApoE Cholesterol transport ↓ 
72/84 Lehtimäki et al. 1995 
↔ 20/10 Merched et al. 1998 
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Table 2 (continued). Candidate CSF biomarkers for Alzheimer’s disease 
Biomarker Function Findings n (AD/control) References 
ApoE Cholesterol transport 
↔ 83/88 Molina et al. 1999 
↑ 76/34 Yamauchi et al. 1999 
↑ 27/70 Rösler et al. 2001 
↔ 32/10 Csernansky et al. 2002 
↓ 15/12 Davidsson et al. 2002 
↓ 7/7 Puchades et al. 2003 
↑ 52/44 Finehout et al. 2007 
↑ 12/12 Sihlbom et al. 2008 
↓ 47/43 Roher et al. 2009 
↔ 66/33 Hu et al. 2010 
↔ 91/242 Craig-Schapiro et al. 
2011 ↔ 24/24 Perrin et al. 2011 
↓ 33/20 Vafadar et al. 2012 
Apo H Multifunction ↑ 10/10 Abdi et al. 2006 
RBP Retinol carrier 
↑ 15/12 Davidsson et al. 2002 
↓ 7/7 Puchades et al. 2003 
↑ 10/10 Abdi et al. 2006 
↓ 30/30 Jung et al. 2008 
S100A Calcium binding ↑ 4/4 Qin et al. 2009 
↓ 24/24 Perrin et al. 2011 
S100B Calcium binding 
↔ 68/25 Peskind et al. 2001 
↑ 31/49 Petzold et al. 2003 
↑ 18/14 Jesse et al. 2009 
SORL1 Neuronal ApoE 
receptor 
↓ 13/13 Ma et al. 2009 
↑ 29/27 Ikeuchi et al. 2010 
NCAM Cell adhesion 
↑ 3/3 Yin et al. 2009 
↑ 137/30 Buchhave et al. 2010 
↓ 66/33 Hu et al. 2010 
↓ 24/24 Perrin et al. 2011 
Substance P Neuropeptide 
↓ 13/15 Martinez et al. 1993b 
↔ 27/70 Rösler et al. 2001 
↓ 38/19 Ernst et al. 2010 
AD7c-NTP Membrane 
phosphoprotein 
↑ 89/18 Monte et al. 1997 
↑ 35/16 Kahle et al. 2000 
 
↑ increased; ↓ decreased; ↔ no significant alterations. Control refers to healthy subjects. 
NfH: Neurofilament heavy chain; NfL: Neurofilament light chain; TG: Transglutaminase; sAPP: Soluble 
amyloid precursor protein; sAPPβ: Soluble amyloid precursor protein β; sAPPα: Soluble amyloid 
precursor protein α; GFAP : Glial fibrillary acidic protein; IL-1 beta: Interleukin-1 beta; sIL-1R: Soluble 
interleukin 1 receptor; IL-6: Interleukin 6; sIL-6R: Soluble interleukin 6 receptor; Gp130: Glycoprotein 
130; IL-11: Interleukin 11; IL-7: Interleukin 7; TRAIL-R3: TNF-related apoptosis-inducing ligand 
receptor; MIF:  Macrophage migration inhibitory factor; PG: Prostaglandins; C3: Complement 
component 3; C4: Complement component 4; MCP-1: Monocyte chemotactic protein 1; TNF-α: 
Tumor necrosis factor alpha; sTNFR: Soluble TNF receptor; GAP-43: Growth associated protein 43; 
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TGFβ-1: Transforming growth factor beta 1; PEDF: Pigment epithelium-derived factor; VEGF: Vascular 
endothelial growth factor;  VGF: Nerve growth factor inducible; HNE: 4-Hydroxynonenal; 8-OHdG: 8-
Hydroxydeoxyguanosine; 3-NT: 3-Nitrotyrosine; SOD1: Superoxide dismutase 1; hFABP: Heart-type 
fatty acid binding protein; MMP-2: Matrix metalloproteinase 2; MMP-3: Matrix metalloproteinase 3; 
MMP-9: Matrix metalloproteinase 9; MMP-10: Matrix metalloproteinase 10; PP: Pancreatic 
polypeptide; TIMP-1: Tissue inhibitor of metalloproteinase 1; TIMP-2: Tissue inhibitor of 
metalloproteinase 2; IGF-1: Insulin-like growth factor 1; IGFBP: Insulin-like growth factor binding 
protein; ACT: α1-Antichymotrypsin; ZAG: Zinc α2-glycoprotein; ATIII: Antithrombin III; CNDP1: 
Carnosinase 1; HVA: Homovanillic acid; 5HIAA:  5-hydroxy-indoleacetic acid; MHPG: 3-methoxy-4-
hydroxyphenylglycol; AChE: Acetylcholinesterase; ACE: Angiotensin converting enzyme; BACE1: Beta-
site amyloid precursor protein (APP)-cleaving enzyme 1; TACE: Tumor necrosis factor-α-converting 
enzyme;  Cg: Chromogranin; VSNL1: Visinin-like protein 1; Apo AI: Apolipoprotein A1; Apo AII: 
Apolipoprotein A2; Apo E: Apolipoprotein E; Apo H: Apolipoprotein H (β2-glycoprotein I); RBP: 
Retinol-binding proteins; S100A: Calcium-binding protein A; S100B: Calcium-binding protein B; SORL1: 
Sortilin-related receptor; NCAM: Neural cell adhesion molecule; AD7c-NTP: AD-associated neuronal 
thread protein. 
 
These complementary candidate biomarkers are more controversial and for most of 
them different studies reported different changes (increased and decreased levels). 
Neurofilament proteins have been suggested as strong candidates, particularly to 
differentiate AD from other related dementias (Sjogren et al., 2000b; de Jong et al., 2007; 
Petzold et al., 2007). These proteins are major neuronal structural elements and increased 
levels reflect axonal degeneration. The same principle applies to other cytoskeletal proteins 
as GFAP. Some other molecules pointed as more promising are closely related with AD 
pathology, like BACE-1, APP fragments or cholesterol carriers and metabolites (Cedazo-
Minguez et al., 2010), despite the variability between studies seen so far. Inflammatory 
mediators are usually elevated whereas neurotrophic factors change in the opposite 
direction, as expected given the pathological mechanisms. VSNL1 (also called VILIP-1) is a 
calcium/binding protein and it is released into CSF from damaged neurons. In accordance, 
several studies reported elevated levels, raising the hope that it could be a useful biomarker 
for AD (Lee et al., 2008). 
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4. Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most common neurological disorder after 
Alzheimer’s disease, affecting over 6.3 million people worldwide, a prevalence that is 
expected to double by 2030 (European Brain Council, 2011). In the USA alone, the 
combined direct and indirect costs of this disease are projected to be nearly US$25 million 
per year (Parkinson’s Disease Foundation, 2013). 
More than 90% of the cases are sporadic, where no cause is identified, while 5 to 10% 
represent familial inherited forms resulting from mutations in genes involved in the disease 
(Kroksveen et al., 2011). The mean age of onset for idiopathic PD is approximately 60 years. 
 
4.1. Clinical presentation and diagnosis 
 As for other neurodegenerative diseases, most of the symptoms in PD occur after a loss 
of more than 70% of dopaminergic neurons in substantia nigra within the brain stem. This 
area controls motor functions, which explains the main symptomatology, such as resting 
tremor, rigidity, bradikynesia and postural instability. Other less frequent motor symptoms 
are the freezing phenomenon and decreased facial movements or expressions (Fahn, 2003). 
Along with motor impairment often arise additional non-motor symptoms, including 
constipation, olfaction loss, sleep disturbances, mood disorders, depression, cognitive deficits, 
sexual and bladder problems, among others. These symptoms can even precede the motor 
ones, and could be helpful to the diagnostic, despite being shared with some related diseases 
(Waragai et al., 2013). 
 Making an accurate diagnosis is difficult, particularly at early stages. It is commonly based 
on the presence of two of the three key signs: resting tremor, bradikynesia and rigidity. 
There are no standard diagnostic criteria, so diagnosis usually relies on this clinical 
information and neurological exams, which may include imaging techniques like MRI, CT and 
PET-Scan. Additional tests could be used for trying to exclude other diseases that could 
mimic PD, since the absolute diagnosis can only be made by brain autopsy. One of these 
tests is a positive response to levodopa, a drug that temporarily restores dopamine levels in 
the brain (Jankovic, 2008).  
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4.2. Pathological features 
 The most important neuropathological feature of Parkinson’s disease is dopaminergic cell 
loss within the substantia nigra along with the deposition of intracellular protein-rich 
inclusions named Lewy bodies (LB) (Dickson et al., 2009). These inclusions are composed 
mainly by fibrillar aggregates of α-synuclein protein. Dopaminergic neurons in the substantia 
nigra project to the striatum, therefore the nigral cell loss results in the depletion of striatal 
dopamine, ultimately responsible for characteristic motor symptoms. However, as the non-
motor clinical signs could suggest, α-synuclein pathology extends to other brain regions and 
to nondopaminergic cell types (Rodriguez-Oroz et al., 2009).  
 Regardless of being a complex disease and the possible involvement of different 
susceptibility genes and environmental factors, aggregation of α-synuclein is proposed as the 
central event leading to neurotoxicity. It is still not clear which forms are more toxic, 
oligomers or fibrils, and how exactly these abnormalities lead to neurodegeneration, or even 
the role of mitochondrial dynamics and response to oxidative stress (Shulman et al., 2011). 
Most likely, toxic forms of α-synuclein may overwhelm molecular chaperones, lysosomes 
and the ubiquitin proteasome system, leading to mitochondrial dysfunction, disruption of 
axonal transport and synaptic loss (Lee et al., 2006). 
 
4.3. CSF biomarkers in PD 
Similarly to AD and other neurodegenerative disorders, the most promising biomarkers 
for PD are based in suggested pathogenic pathways, either specific (e.g. α-synuclein and DJ-1) 
or related with more general neurodegenerative mechanisms like lysosomal and 
mitochondrial dysfunction, oxidative stress and neuroinflammation  (Parnetti  et al., 
2013)(Figure 3). 
 
 
 
 
Figure 3 (next page). Schematic representation of pathogenic pathways underlying putative 
biomarkers for Parkinson’s disease. The aggregation and deposition of α-synuclein is triggered by 
oxidative species and mitochondrial and lysosomal dysfunction, but could also exacerbate those same 
malfunctions. As a result, levels of α-synuclein decrease in CSF and markers of neuroinflammation 
and oxidative stress are usually elevated. Dementia in PD could also be linked to the same markers 
of AD, namely amyloid peptides and tau protein. (Molecules name abbreviations are detailed in Table 
3). 
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In Table 3 are summarized the major findings for those putative biomarkers, with at least 
one study reporting an increase or decrease value. 
 
Table 3. Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
Key markers 
α-Synuclein 
Poorly understood 
(Potential 
microtubule  
associated protein; 
chaperone) 
  
↔ 12/10 Borghi et al. 2000 
↓ 33/38 Tokuda et al. 2006 
↓ 8/13 Mollenhauer et al. 2008 
↔ 15/55 Ohrfelt et al. 2009 
↓ 117/132 Hong et al. 2010 
↓ 32/28 Tokuda et al. 2010 
↔ 38/20 Foulds et al. 2011 
↓ 324/99 Mollenhauer et al. 2011 
↔ 23/29 Park et al. 2011 
↓ 38/32 Parnetti et al. 2011 
↓ 126/137 Shi et al. 2011 
↔ 58/183 Aerts et al. 2012 
↓ 11/11 Tateno et al. 2012 
↓ 209/204 Wang et al. 2012 
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Table 3 (continued). Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
α-Synuclein Poorly understood 
 
↓ 78/48 Mollenhauer et al. 2013 
↓ 53/50 van Dijk et al. 2013c 
↓ 38/52 Wennström et al. 2013 
DJ-1 Transcription 
regulator 
↑ 40/38 Waragai et al. 2006 
al., 2006 ↓ 117/132 Hong et al. 2010 
↓ 126/137 Shi et al. 2011 
Markers related with axonal degeneration 
Aβ42 
Poorly understood 
(activation of kinases; 
transcription factor) 
↔ 15/19 Kanemaru et al. 2000 
↔ 23/32 Sjogren et al. 2000 
↓ 15/17 Sjogren et al. 2002 
↔ 48/32 Holmberg et al. 2003 
(2003)20 ↔ 12/24 Lins et al. 2004 
↔ 30/34 Verbeek et al. 2004 
↓ 96/41 Mollenhauer et al. 2006 
↔ 11/19 Mollenhauer et al. 2007 
↓ 20/20 Parnetti et al. 2008 
↓ 40/95 Zhang et al. 2008 
↓ 40/30 Compta et al. 2009 
↓ 109/36 Alves et al. 2010 
↓ 122/150 Montine et al. 2010 
↔ 32/30 Přikrylová et al. 2010 
↔ 38/32 Parnetti et al. 2011 
↓ 126/137 Shi et al. 2011 
Tau protein 
Microtubule 
stabilization 
↔ 15/31 Blennow et al. 1995 
↔ 73/77 Arai et al. 1997 
↔ 26/25 Molina et al. 1997 
↔ 115/15 Jansen et al. 1998 
↔ 29/16 Kahle et al. 2000 
↔ 15/19 Kanemaru et al. 2000 
↔ 23/32 Sjogren et al. 2000 
↔ 15/17 Sjogren et al. 2001 
↔ 12/24 Lins et al. 2004 
↔ 14/61 Paraskevas et al. 2005 
↑ 96/41 Mollenhauer et al. 2006 
↑ 11/19 Mollenhauer et al. 2007 
↔ 10/27 Borroni et al. 2008 
↔ 20/20 Parnetti et al. 2008 
↓ 40/95 Zhang et al. 2008 
↔ 40/30 Compta et al. 2009 
↔ 109/36 Alves et al. 2010 
↔ 122/150 Montine et al. 2010 
↑ 32/30 Přikrylová et al. 2010 
↔ 38/32 Parnetti et al. 2011 
↓ 126/137 Shi et al. 2011 
NfH Axonal structure 
protein 
↔ 22/45 Brettschneider et al. 
2006c ↔ 20/40 Steinacker et al. 2011 
TG Protein cross-linking ↑ 54/34 Vermes et al. 2004 
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Table 3 (continued). Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
sAPP Neurotrophic factor ↓ 10/9 Henriksson et al. 1991 
Markers related with inflammation and immune response 
IL-1 beta Immune response 
↔ 20/42 Pirtilla et al. 1994 
↑ 22/12 Blum-Degen et al. 1995 
IL-6 Immune response 
↑ 22/12 Blum-Degen et al. 1995 
↑ 22/22 Müller et al. 1998 
IL-8 Immune response ↑ 40/95 Zhang et al. 2008 
C3 
Inflammatory 
response 
↓ 10/9 Finehout et al. 2005 
↓ 23/24 Guo et al. 2009 
C4 Inflammatory 
response 
↓ 10/9 Finehout et al. 2005 
↓ 23/24 Guo et al. 2009 
↓ 6/6 Wang et al. 2013 
Factor B Inflammatory 
response 
↓ 10/9 Finehout et al. 2005 
Dermcidin Immu e response ↓ 23/24 Guo et al. 2009 
MCP-1 
Inflammatory 
response 
↑ 25/16 Nagata et al. 2007 
↔ 8/13 Choi et al. 2008 
TNF-α Immune response 
↑ 15/16 Mogi et al. 1994 
↑ 38/10 Le et al. 1999 
Neopterin Immune response 
↓ 18/28 Fujishiro et al. 1990 
↑ 22/11 Widner et al. 2002 
Markers related with neuroprotection 
BDNF Neurotrophic factor 
↓ 40/95 Zhang et al. 2008 
↑ 24/24 Salehi et al. 2009 
GAP-43 Axonal growth ↓ 23/32 Sjogren et al. 2000 
TGFβ-1 Growth factor 
↑ 30/16 Vawter et al. 1996 
↔ 24/25 Rota et al. 2006 
PEDF Neurotrophic factor ↑ 23/24 Guo et al. 2009 
Neurosin Serine protease ↓ 38/52 Wennström et al. 2013 
Clusterin Chaperone 
↔ 18/11 Lidström et al. 2001 
↓ 23/24 Guo et al. 2009 
↑ 3/3 Yin et al. 2009 
↑ 32/30 Přikrylová et al. 2010 
↑ 43/49 Maarouf et al. 2012 
↔ 52/50 van Dijk et al. 2013a 
Cystatin C 
Cysteine protease 
inhibitor 
↓ 51/52 Maetzler et al. 2010 
↔ 32/30 Přikrylová et al. 2010 
↔ 18/15 Yamamoto et al. 2010 
β2microglobulin HLA complex 
↓ 59/44 Mogi et al. 1989 
↑ 40/95 Zhang et al. 2008 
↔ 56/24 Constantinescu et al. 2010b 
Markers related with oxidative stress 
HNE Lipid peroxidation ↑ 10/10 Selley. 1998 
8-OHdG DNA oxidative 
damage 
↑ 48/21 Kikuchi et al. 2002 
↑ 48/13 Gmitterová et al. 2009 
↑ 20/20 Isobe et al. 2010 
SOD1 Detoxification  ↔ 26/26 Marttila et al. 1988 
↔ 12/58 De Deyn et al. 1998 
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Table 3 (continued). Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
SOD1 Detoxification  
↓ 22/41 Boll et al. 2008 
↑ 23/24 Guo et al. 2009 
↔ 6/6 Wang et al. 2013 
Nitrate 
NO 
biotransformation 
↓ 103/20 Kuiper et al. 1994b 
↔ 11/17 Ikeda et al. 1995 
↔ 31/38 Molina et al. 1996 
↔ 20/21 Shukla et al. 2006 
↑ 22/41 Boll et al. 2008 
Haptoglobin Hemoglobin binding 
↑ 10/10 Abdi et al. 2006 
↓ 23/24 Guo et al. 2009 
MDA Lipid oxidation 
↑ 31/31 Ilic et al. 1998 
↑ 34/34 Ilic et al. 1999 
↔ 20/21 Shukla et al. 2006 
Transferrin Iron binding 
↔ 12/11 Loeffler et al. 1994 
↔ 90/21 van Kamp et al. 1995 
↑ 14/14 Sinha et al. 2009 
Ceruloplasmin Copper transport 
↔ 12/11 Loeffler et al. 1994 
↓ 35/26 Boll et al. 1999 
↓ 10/10 Abdi et al. 2006 
↓ 22/41 Boll et al. 2008 
Others 
TIMP-1 MMP-1 inhibitor ↑ 13/41 Lorenzl  et al. 2003 
Glutamate Excitotoxicity 
↓ 20/11 Ondarza et al. 1994 
↔ 31/45 Jiménez-Jiménez et al. 
1996 ↓ 10/10 Mally et al. 1997 
↔ 108/21 Kuiper et al. 2000 
DBH 
Cathecolamine 
biosynthesis 
↓ 5/5 Matsui et al. 1981 
↓ - Hurst et al. 1985 
↓ 34/25 Mogi et al. 1988 
↔ 35/34 Hartikainen et al. 1992 
Transthyretin Thyroid hormone 
binding 
↓ 23/24 Guo et al. 2009 
↓ 3/3 Yin et al. 2009 
↑ 43/49 Maarouf et al. 2012 
↑ 103/72 Maetzler et al. 2012 
IGF-1 Cell proliferation ↑ 38/38 Mashayekhi et al. 2010 
IGFBP IGF binding protein ↑ 38/38 Mashayekhi et al. 2010 
α1-Antitrypsin Protease inhibitor ↑ 23/24 Guo et al. 2009 
Autotaxin Lipid signaling ↑ 23/24 Guo et al. 2009 
Tetranectin Plasminogen binding 
↓ 11/10 Wang et al. 2010 
↓ 6/6 Wang et al. 2013 
Fibrinogen Coagulation cascade 
↔ 10/10 Abdi et al. 2006 
↓ 3/3 Yin et al. 2009 
↓ 43/49 Maarouf et al. 2012 
Osteopontin Stress; inflammation ↑ 30/30 Maetzler et al. 2007 
Copper Micronutrient  
↑ 24/34 Pall et al. 1987 
↔ 11/11 Gazzaniga et al. 1992 
↔ 37/37 Jiménez-Jiménez et al. 
1998a 
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Table 3 (continued). Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
Copper Micronutrient  
↑ 35/26 Boll et al. 1999 
↑ 22/41 Boll et al. 2008 
↑ 20/15 Hozumi et al. 2011 
Orexin Neurotransmitter 
↔ 7/48 Ripley et al. 2001 
↓ 19/19 Drouot et al. 2003 
↔ 10/20 Baumann et al. 2005 
↓ 9/17 Fronczek et al. 2007 
HVA Dopamine metabolite 
↓ 31/10 Van Woert et al. 1970 
↓ 23/25 Chase et al. 1972 
↓ 11/24 Curzon et al. 1972 
↓ 26/11 Gumpert et al. 1973 
↓ 75/15 Davidson et al. 1977 
↓ 11/30 Ichikawa. 1986 
↓ 36/19 Jolkkonen et al. 1986 
↔ 10/15 Zubenko et al. 1986 
↓ 14/4 Kurlan et al. 1988b 
↓ 35/34 Hartikainen et al. 1992 
↓ 38/12 Strittmatter et al. 1992 
↓ 61/26 Chia et al. 1993 
↓ 23/15 García et al. 1995 
↓ 20/16 Cheng et al. 1996 
↔ 35/11 Strittmatter et al. 1996 
↓ 11/13 Kanemaru et al. 1998 
5HIAA Serotonin metabolite 
↓ 27/10 Van Woert et al. 1970 
↓ 23/25 Chase et al. 1972 
↓ 11/24 Curzon et al. 1972 
↓ 26/11 Gumpert et al. 1973 
↔ 75/15 Davidson et al. 1977 
↓ 11/30 Ichikawa. 1986 
↓ 35/34 Hartikainen et al. 1992 
↔ 38/12 Strittmatter et al. 1992 
↔ 61/26 Chia et al. 1993 
↑ 23/15 García et al. 1995 
↔ 35/11 Strittmatter et al. 1996 
AChE Serine protease 
↔ 36/19 Jolkkonen et al. 1986 
↔ 10/15 Zubenko et al. 1986 
↔ 11/5 Ruberg et al. 1986 
↔ 13/19 Ruberg et al. 1987 
↔ 16/9 Manyam et al. 1990b 
↓ 35/34 Hartikainen et al. 1992 
↔ 103/20 Konings et al. 1995 
ACE 
Blood pressure 
regulation 
↓ 10/30 Zubenko et al. 1985 
↓ 10/15 Zubenko et al. 1986 
↑ 106/20 Konings et al. 1994 
β-glucosidase Glycolipid metabolism ↓ 12/20 Balducci et al. 2007 
↔ 58/52 van Dijk et al. 2013b 
Somatostatin Neuropeptide ↓ 39/- Dupont et al. 1982 
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Table 3 (continued). Candidate CSF biomarkers for Parkinson’s disease 
Biomarker Function Findings n (PD/control) References 
Somatostatin Neuropeptide 
↓ 36/19 Jolkkonen et al. 1986 
↔ - Volicer et al. 1986 
↓ - Unger et al. 1988 
↓ 68/6 Jost et al. 1990 
↓ 35/11 Masson et al. 1990 
↔ 35/34 Hartikainen et al. 1992 
↓ 38/12 Strittmatter et al. 1992 
↑ 33/26 Espino et al. 1995 
↓ 35/11 Strittmatter et al. 1996 
CgA Neuroendocrine 
secretion 
↓ 10/10 Kaiserová et al. 2013 
33 VDBP Vitamin D transport ↔ 10/10 Abdi et al. 2006 
↑ 40/95 Zhang et al. 2008 
ApoAI Lipid metabolism 
↓ 20/91 Harrington et al. 1984 
↓ 40/95 Zhang et al. 2008 
↓ 3/3 Yin et al. 2009 
↑ 11/10 Wang et al. 2010 
↓ 43/49 Maarouf et al. 2012 
↑ 6/6 Wang et al. 2013 
ApoAII Lipid metabolism ↓ 40/95 Zhang et al. 2008 
ApoE Cholesterol transport 
↔ 10/10 Abdi et al. 2006 
↓ 40/95 Zhang et al. 2008 
↑ 23/24 Guo et al. 2009 
↑ 43/49 Maarouf et al. 2012 
↑ 23/24 Guo et al. 2009 
Apo H Multifunction ↓ 10/10 Abdi et al. 2006 
ADH Peptide hormone ↓ 11/21 Sundquist et al. 1983 
↓ - Olsson et al. 1987 
NPY Neuropeptide ↔ 8/9 Yaksh et al. 1990 
↓ 10/20 Martignoni et al. 1992 
Substance P Neuropeptide 
↓ - Pezzoli et al. 1994 
↔ 8/14 Matsuishi et al. 1996a 
↔ 23/16 Matsuishi et al. 1999 
Enkephalins  
Nociception 
regulation 
↓ 8/9 Yaksh et al. 1990 
↓ 32/13 Baronti et al. 1991 
↑ - Pezzoli et al. 1994 
CCK Fat, protein digestion ↓ 20/68 Lotstra et al. 1985 
 
↑ increased; ↓ decreased; ↔ no significant alterations; Control refers to healthy subjects. 
DJ-1: Parkinson disease (autosomal recessive, early onset) 7 (PARK7); Aβ42: Beta amyloid; NfH: 
Neurofilament heavy chain; NfL: Neurofilament light chain; TG: Transglutaminase; sAPP: Soluble 
amyloid precursor protein;IL-1 beta: Interleukin-1 beta; ;  IL-2: Interleukin 2; IL-6: Interleukin 6; IL-8: 
interleukin 8; C3: Complement component 3; C4: Complement component 4; MCP-1: Monocyte 
chemotactic protein 1; TNF-α: Tumor necrosis factor alpha; BDNF: Brain derived neurotrophic factor; 
GAP-43: Growth associated protein 43; TGFβ-1: Transforming growth factor beta 1; PEDF: Pigment 
epithelium-derived factor; Flt3: FMS-like tyrosine kinase 3; HNE: 4-Hydroxynonenal; 8-OHdG: 8-
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Hydroxydeoxyguanosine; SOD1: Superoxide dismutase 1; SOD2: Superoxide dismutase 2; GPX: 
Glutathione peroxidase; MDA: Malondialdehyde; MMP-2: Matrix metalloproteinase 2; MMP-9: Matrix 
metalloproteinase 9; TIMP-1: Tissue inhibitor of metalloproteinase 1; TIMP-2: Tissue inhibitor of 
metalloproteinase 2; DBH: Dopamine beta hydroxylase; IGF-1: Insulin-like growth factor 1; IGFBP: 
Insulin-like growth factor binding protein; HVA: Homovanillic acid; 5HIAA:  5-hydroxy-indoleacetic 
acid; MHPG: 3-methoxy-4-hydroxyphenylglycol; AChE: Acetylcholinesterase; ACE: Angiotensin 
converting enzyme; CgA: Chromogranin A; VDBP: vitamin D binding protein; Apo AI: Apolipoprotein 
A1; Apo AII: Apolipoprotein A2; Apo E: Apolipoprotein E; Apo H: Apolipoprotein H (β2-glycoprotein 
I); AST: Aspartate aminotransferase; ADH: Antidiuretic hormone; NPY: Neuropeptide Y; CCK: 
Cholecystokinin 8. 
 
In contrast with Alzheimer’s disease, there is still no validated biomarker for PD, but 
some promising candidates are emerging. This is particularly true for those species more 
related with pathogenesis, such as α-syn, DJ-1, Aβ42 and tau protein (Nyhlén et al., 2010). 
Aggregation and plaque deposition of α-syn and Aβ42 is responsible for the low levels found 
in CSF. Although DJ-1 have been associated with PD in familial and sporadic forms, probably 
acting as a protease or chaperone, the results of different studies are still inconclusive and 
data is inconsistent (Constantinescu et al., 2013). On the other hand, biomarkers reflecting 
lysosomal dysfunction, pointed as an early event in PD pathogenesis, could be useful for 
complementing others in order to achieve a correct diagnosis (Parnetti  et al., 2013).  As 
expected, markers of oxidative stress and inflammation are generally elevated in PD patients. 
Two related candidate biomarkers, ceruloplasmin and copper, present low and high levels 
respectively, in almost all CSF studies. Cooper acts as an antioxidant when bound to 
proteins such as ceruloplasmin but when in its free form the effect is just the opposite. The 
low levels of cooper binding proteins in PD are probably responsible for the release and high 
levels of free metal (Boll et al., 2008). 
The limitations presented by the lack of sufficient biomarker studies are being addressed 
by some global initiatives, such as the Parkinson Progression Marker Initiative, raising the 
hope of reaching validated useful biomarkers in a near future (Parkinson Progression Marker 
Initiative, 2011). 
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5. Amyotrophic lateral sclerosis  
 
Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is the most 
common neuromuscular disease, characterized by progressive degeneration and death of 
motor neurons, leading to death within 3 to 5 years after disease onset. It generally affects 
more men than women, at ages among 40 and 70 years (ALS Foundation for Life, 2013). The 
global annual incidence is estimated to be 0.4 to 3.7 per 100,000 individuals and the 
prevalence ranged from 0.2 to 1.2 per 10,000. The costs for caring just one patient with ALS 
could reach US$200,000 a year (Chio et al., 2012). 
About 90 to 95% of cases are labeled sporadic, since the patients do not seem to have 
any clear associated risk factors or a family history for ALS. The remaining cases are 
inherited, and mutations in more than ten different genes have been found to cause familial 
ALS. More than 50% of all familial cases (and also some sporadic) results from defects in 
C9orf72 and SOD1 genes (Kruger et al., 2013). 
 
5.1. Clinical presentation and diagnosis 
The disease usually becomes apparent with symptoms like fasciculations, muscular 
cramps and weakness mainly focal and unilateral, coordination and speech impairments and 
swallowing difficulties. According to the part of the body first affected, the disease could be 
classified as classic, bulbar, limb, pyramidal and respiratory, to give some examples (Chio et 
al., 2011). As the disease progress, symptoms spread to other body parts and eventually the 
individuals will not be able to stand or walk, and will experience serious difficulties in eating 
and breeding. In most cases the weakness of respiratory muscles is responsible for 
respiratory failure and consequent patient’s death. Since cognitive functions are mostly intact, 
many patients could also suffer from anxiety and depression (National Institute of 
Neurologic Disorders and Stroke, 2013). 
Similarly to almost all neurodegenerative diseases, the clinical diagnosis of ALS is difficult, 
particularly at early stages, but the presence of upper and lower motor neuron signs is 
strongly suggestive. It is based on El Escorial and the Awaji criteria, and a full medical history 
and neurologic evaluation could help to differentiate ALS from other disorders. At the same 
time, some other exams like MRI and electromyography (EMG) could detect ALS related 
alterations, but most importantly can reveal other causes for the symptoms (Brooks et al., 
2000; de Carvalho  et al., 2008). 
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5.2. Pathological features 
The motor neurons affected and surrounding reactive astrocytes show different inclusion 
bodies as pathological hallmarks (Barbeito et al., 2004). The most common are ubiquitinated 
inclusions, which suggest that the proteasome pathway is activated in this disease, and they 
are classified as Lewy body-like hyaline inclusions and skein-like inclusions (Kawashima et al., 
1998). Some other proteins identified in these aggresomes include SOD1, TDP-43, FUS and 
neurofilament proteins. Additionally, is possible to find Bunina bodies, which are cystatin C 
containing inclusions (Lowe, 1994; Sasaki et al., 1994).  
Numerous mechanisms have been proposed for the pathological process in ALS, but 
most researchers agree that is possibly a combination of some or all that leads to the 
development of disease (Pasinelli et al., 2006). Mutated or misfolded proteins from inclusion 
bodies could be linked to defective axonal transport, Golgi fragmentation and ER stress. The 
excitotoxicity also appears to have an important role and could occur by exposure to 
excitotoxins, overactivation of glutamate receptors, oxidative stress, dysfunctions in calcium 
homeostasis or even cytoskeletal abnormalities with accumulation of neurofilaments. The 
resulting mitochondrial dysfunction and neuroinflammation can induce apoptosis and 
neuronal death (Strong, 2001; Shaw, 2005; Murata et al., 2008).  
 
5.3. Putative CSF biomarkers for ALS 
Similarly to the diseases described above, insights in the pathological mechanisms of ALS 
can be useful as a starting point for biomarker discovery. Some mechanisms and molecules 
involved in motor neuron degeneration that could be useful in biomarker development are 
represented in Figure 4 (Kiernan et al., 2011). Table 4 summarizes the most relevant studies 
in this area for the more prominent candidates, with at least one report of increased or 
decreased levels in CSF. 
 
 
 
 
 
Figure 4 (next page). Schematic illustration of the main pathophysiological mechanisms proposed for 
ALS. Neurodegeneration could result from protein aggregation and consequent mitochondrial 
dysfunction, defects in calcium homeostasis and axonal transport, malfunction of neuroprotective 
enzymes like SOD1, and increased neuronal vulnerability to free radicals, glutamate excitotoxicity 
and inflammatory mediators. 
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Table 4. Candidate CSF biomarkers for Amyotrophic lateral sclerosis 
Biomarker Function Findings n (ALS/control) References 
Markers related with neuroprotection 
TDP-43 
DNA/RNA binding 
protein 
↑ 27/25 Steinacker et al. 2008 
↑ 30/29 Kasai et al. 2009 
↑ 27/50 Noto et al. 2011 
PEDF Neurotrophic factor 
↑ - Bilak et al. 1999 
↑ 15/22 Kuncl et al. 2002 
VEGF Angiogenesis 
↓ 24/34 Devos et al. 2004 
↑ 30/30 Iłzecka. 2004 
↓ 20/20 Moreau et al. 2006 
↓ 20/20 Just et al. 2007 
↓ 42/16 Nagata et al. 2007 
↓ 40/40 Moreau et al. 2009 
↑ 42/34 Tateishi et al. 2010 
↑ 50/50 Gupta et al. 2011 
PGRN Neurotrophic factor 
↑ 91/56 Philips et al. 2010 
↓ 68/60 Steinacker et al. 2011 
Cystatin C 
Cysteine protease 
inhibitor 
↓ 23/31 Ranganathan et al. 2005 
↓ 36/21 Pasinetti et al. 2006 
↓ 14/29 Tsuji-Akimoto et al. 2009 
↓ 100/141 Ryberg et al. 2010 
↓ 44/69 Wilson et al. 2010 
↔ 31/99 Yamamoto et al. 2010 
↓ 23/46 Wilson et al. 2013 
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Table 4 (continued). Candidate CSF biomarkers for Amyotrophic lateral sclerosis 
Biomarker Function Findings n (ALS/control) References 
TGFβ-1 Growth factor ↑ 24/15 Iłzecka et al. 2002 
S100b Neurotrophic factor 
↓ 20/20 Süssmuth et al. 2003 
↓ 75/28 Süssmuth et al. 2010 
GDNF Neurotrophic factor ↑ 15/11 Grundström et al. 2000 
FGF-2 Growth factor ↑ 15/10 Johansson et al. 2003 
Flt3 Neurotrophic factor ↑ 23/23 Iłzecka. 2006 
HGF Growth factor 
↑ 12/11 Kern et al. 2001 
↑ 10/32 Tsuboi et al. 2002 
Markers related with axonal degeneration 
NfH 
Axonal structure 
protein 
↑ 69/106 Brettschneider et al. 2006a 
↑ 29/15 Reijn et al. 2009 
↑ 50/73 Kuhle et al. 2010 
↑ 71/92 Ganesalingam et al. 2011 
↑ 10/6 Mendonça et al. 2011 
↑ 68/60 Steinacker et al. 2011 
↑ 150/140 Ganesalingam et al. 2013 
NfL 
Axonal structure 
protein 
↑ 12/45 Rosengren et al. 1996 
↑ 11/5 Norgren et al. 2003 
↑ 79/246 Zetterberg et al. 2007 
↑ 29/15 Reijn et al. 2009 
↑ 37/46 Tortelli et al. 2012 
Tau protein 
Microtubule 
stabilization 
↔ 11/17 Sjogren et al. 2002 
↑ 20/20 Süssmuth et al. 2003 
↔ 18/75 Jiménez-Jiménez et al. 2005 
↔ 30/49 Brettschneider  et al. 2006b 
↑ 69/33 Brettschneider  et al. 2006a 
↑ 75/47 Süssmuth et al. 2010 
TGases Protein cross-linking ↑ 17/21 Fujita et al. 1998 
Aβ42 Poor understood ↓ 11/17 Sjogren et al. 2002 
sAPP Neurotrophic factor ↓ 68/60 Steinacker et al. 2011 
Markers related with inflammation and immune response 
IL-6 Immune response 
↑ 27/21 Sekizawa et al. 1998 
↔ 20/20 Moreau et al. 2005 
↔ 16/16 Klimek et al. 1995 
IL-8 Immune response ↑ 41/33 Mitchell et al. 2009 
↑ 20/20 Kuhle et al. 2009 
C3 
Inflammatory 
response 
↑ 13/23 Annunziata et al. 1985 
↑ 71/92 Ganesalingam et al. 2011 
C4 
Inflammatory 
response 
↔ 13/23 Annunziata et al. 1985 
↑ 15/12 Tsuboi et al. 1994 
G-CSF Immune response ↑ 37/33 Tanaka et al. 2006 
↑ 42/34 Tateishi et al. 2010 
MCP-1 
Inflammatory 
response 
↑ 29/11 Wilms et al. 2003 
↑ 16/29 Henkel et al. 2004 
↔ 31/38 Simpson et al. 2004 
↑ 27/30 Baron et al. 2005 
↑ 37/33 Tanaka et al. 2006 
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Table 4 (continued). Candidate CSF biomarkers for Amyotrophic lateral sclerosis 
Biomarker Function Findings n (ALS/control) References 
MCP-1 
Inflammatory 
response 
↑ 42/16 Nagata et al. 2007 
↑ 20/20 Kuhle et al. 2009 
↑ 42/34 Tateishi et al. 2010 
↑ 50/50 Gupta et al. 2011 
↑ 44/29 Gupta et al. 2012 
PGE2 
Inflammatory 
response 
↑ 17/21 Almer et al. 2002 
↑ 20/20 Iłzecka. 2003 
TNF-α Immune response ↑ 42/34 Tateishi et al. 2010 
Neopterin Immune response ↑ 12/39 Yoshida et al. 1999 
Caspase-1 Inflammatory 
response 
↓ 25/15 Iłzecka et al. 2001 
Galactin-3 Immune response ↑ 30/21 Zhou et al. 2010 
RANTES Immune response ↑ 20/27 Rentzos et al. 2007 
Markers related with oxidative stress 
HNE Lipid peroxidation 
↑ 186/236 Beckman et al. 1993 
↑ 69/49 Simpson et al. 2004 
8-OHdG 
DNA oxidative 
damage 
↑ 23/19 Bogdanov et al. 2000 
↑ 7/14 Ihara et al. 2005 
3-NT Protein nitration  
↑ 18/14 Tohgi et al. 1999b 
↑ 19/19 Tohgi et al. 1999c 
↔ 14/19 Ryberg et al. 2004 
↔ 10/6 Mendonça et al. 2011 
SOD1 Detoxification  
↔ 66/37 Jacobsson et al. 2001 
↓ 18/19 Boll et al. 2003 
↓ 7/14 Ihara et al. 2005 
↑ 30/22 Kokić et al. 2005 
↓ 27/41 Boll et al. 2008 
↔ 11/19 Frutiger et al. 2008 
↔ 96/38 Zetterström et al. 2011 
Glutathione Detoxification  ↑ 12/15 Tohgi et al. 1999b 
GPX Peroxides 
inactivation  
↑ 40/30 Kuźma et al. 2006 
Nitrate NO transformation 
↑ 18/14 Tohgi et al. 1999b 
↑ 18/19 Boll et al. 2003 
↔ 14/25 Pirttilä et al. 2004 
↑ 27/41 Boll et al. 2008 
Iron Radical generator ↔ 30/22 Kokić et al. 2005 
Uric acid Excitotoxicity ↑ 30/22 Kokić et al. 2005 
Others 
MMP-2 Protein degradation 
↔ 18/41 Lorenzl et al. 2003 
↔ 54/36 Fang et al. 2009 
↑ 30/15 Niebroj-Dobosz et al. 2010 
MMP-9 Protein degradation 
↔ 14/20 Beuche et al. 2000 
↑ 54/36 Fang et al. 2009 
↓ 30/15 Niebroj-Dobosz et al. 2010 
TIMP-1 MMP-1 inhibitor 
↔ 14/20 Beuche et al. 2000 
↑ 18/41 Lorenzl et al. 2003 
↔ 30/15 Niebroj-Dobosz et al. 2010 
Glutamate Excitotoxicity ↑ 377/106 Spreux-Varoquaux et al. 
2002 
  
46 
Table 4 (continued). Candidate CSF biomarkers for Amyotrophic lateral sclerosis 
Biomarker Function Findings n (ALS/control) References 
Glutamate Excitotoxicity ↓ 78/78 Wuolikainen et al. 2011 
EPO Erythropoiesis 
↓ 30/49 Brettschneider  et al. 2006b 
↑ 20/20 Just et al. 2007 
↓ 60/53 Brettschneider  et al. 2007 
↓ 15/20 Widl  et al. 2007 
↓ 30/15 Janik et al. 2010 
Transthyretin 
Thyroid hormone 
binding 
↓ 23/31 Ranganathan et al. 2005 
↓ 100/141 Ryberg et al. 2010 
VGF Synaptogenesis 
↓ 36/21 Pasinetti et al. 2006 
↓ 17/21 Zhao et al. 2008 
Insulin Metabolism ↓ 24/40 Bilic et al. 2006 
IGF-1 Cell proliferation 
↔ 14/25 Pirttilä et al. 2004 
↓ 24/40 Bilic et al. 2006 
↑ 54/50 Corbo et al. 2010 
GH Cell growth ↓ 24/40 Bilic et al. 2006 
DJ-1 Transcription 
regulator 
↑ 30/9 Yamashita et al. 2010 
GS Glutamine synthesis ↑ 8/35 Tumani et al. 1999 
Substance P Neuropeptide ↑ 11/16 Matsuishi et al. 1999 
Cytochrome 
C 
Electron transfer ↓ 40/40 Iłzecka. 2007 
7B2 Neuroendocrine 
protein 
↑ 23/31 Ranganathan et al. 2005 
 
↑ increased; ↓ decreased; ↔ no significant alterations; Control refers to healthy subjects. 
TDP-43: TAR DNA-binding protein 43; PEDF: Pigment epithelium-derived factor; VEGF: Vascular 
endothelial growth factor; PGRN: Progranulin; TGFβ-1: Transforming growth factor beta 1; S100b: 
S100 calcium binding protein B; GDNF: Glial cell-derived neurotrophic factor; FGF-2: Basic fibroblast 
growth factor; Flt3: FMS-like tyrosine kinase 3; HGF: Hepatocyte growth factor; NfH: Neurofilament 
heavy chain; NfL: Neurofilament light chain; Aβ42: Beta amyloid; sAPP: Soluble amyloid precursor 
protein; IL-6: Interleukin 6; IL-8: interleukin 8; C3: Complement component 3; C4: Complement 
component 4; G-CSF: Granulocyte colony-stimulating factor; MCP-1: Monocyte chemotactic protein 1; 
PGE2: Prostaglandin E2; TNF-α: Tumor necrosis factor alpha; RANTES: Regulated on activation, normal 
T cell expressed and secreted, also Chemokine (C-C motif) ligand 5; HNE: 4-Hydroxynonenal; 8-
OHdG: 8-Hydroxydeoxyguanosine; 3-NT: 3-Nitrotyrosine; SOD1: Superoxide dismutase 1; GPX: 
Glutathione peroxidase; MMP-2: Matrix metalloproteinase 2; MMP-9: Matrix metalloproteinase 9; 
TIMP-1: Tissue inhibitor of metalloproteinase 1; TIMP-2: Tissue inhibitor of metalloproteinase 2; EPO: 
Erythropoietin;  VGF: Nerve growth factor inducible; IGF-1: Insulin-like growth factor 1; IGFBP-2: 
Insulin-like growth factor binding protein 2; IGFBP-3: Insulin-like growth factor binding protein 3; GH: 
Growth hormone; DJ-1: Parkinson disease (autosomal recessive, early onset) 7 (PARK7); GS: 
Glutamine synthetase; 7B2: Neuroendocrine protein 7B2. 
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The only drug approved for ALS (riluzole) only extends life span in 2 to 3 months, and 
most patients die within 3 years after disease onset (Kruger et al., 2013). Therefore, the 
need for biomarkers, not only for early diagnosis but also for therapies development is even 
more important for this neurodegenerative disease. None of the above candidates have 
reached clinical significance and the future strategy could be a multiprotein profiling, making 
use of advances in molecular techniques.  Nevertheless, the most promising candidates so far 
are probably TDP-43, neurofilament proteins and Cystatin C measurements (Noto et al., 
2011). TDP-43 is a DNA and RNA binding protein, playing a key role in ALS pathogenesis, as 
mutations in the gene encoding this protein are involved in sporadic and familial forms of the 
disease. The CSF levels are raised at early stages of the disease, though they gradually drop, 
probably resulting from the accumulation in neurons with disease progression (Kasai et al., 
2009). Neurofilament proteins are an important component of the axonal skeleton, playing a 
crucial role in maintaining integrity and axonal transport and their dysfunction have been 
implicated in motor neuron degeneration. Concentrations are raised in CSF due to neuronal 
loss, with a reported sensitivity and specificity higher than 90% compared to controls 
(Brettschneider et al., 2006a). Cystatin C is a cysteine protease inhibitor having both a 
neurotoxic and a neuroprotective role and seems to be consistently decreased in ALS 
patients. It is also found in Bunina bodies, which could explain its low levels in CSF 
(Ranganathan et al., 2005). Some other findings have been significant for a better 
understanding of ALS pathogenesis and could be applied as biomarkers in the future. One 
example is high concentrations of excitatory amino acids (e.g. glutamate) in CSF, supporting 
the excitotoxicity hypothesis as a pathological mechanism (Turner et al., 2009). 
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6. Polyglutamine diseases 
 
Polyglutamine diseases are a group of neurodegenerative conditions with a genetic cause, 
resulting from a CAG triplet repeat expansion in a specific gene that produces a pathogenic 
protein containing an expanded tract of glutamines. These mutations could affect ten 
different genes, each one originating a specific disease. Some examples are Huntington’s 
disease (HD) and several spinocerebellar ataxias (SCA), the most common being SCA3, also 
called Machado-Joseph disease (MJD) (Shao et al., 2007). 
Huntington’s is the most common among all polyglutamine diseases with approximately 
30,000 people diagnosed in USA and Canada and roughly 150,000 at risk. In Europe, the 
estimated prevalence is about 4 to 9 per 100,000 individuals, the lower limit being 
approximately the prevalence of all other polyglutamine diseases, particularly spinocerebellar 
ataxias.  The impact is, however, disproportionate to that prevalence, since they tend to 
manifest in middle age and are progressive, resulting not only in enormous costs of care but 
also in lost earnings from individuals affected and possibly some family members (Paulson et 
al., 2011). 
 
6.1. Huntington’s disease clinical features 
Huntington’s disease results from a mutation in the huntingtin (HTT) gene, with a CAG 
pathogenic repeat length of 36 to 121. The mutated protein inclusions are often found in 
nucleus and cytoplasm of neurons located in the striatum and cerebral cortex (Nakamura et 
al., 2007).  
The characteristic features include a progressive movement disorder (chorea), cognitive 
decline culminating in dementia and various psychiatric and behavioral symptoms. The 
course of the disease is slow and some early symptoms include mood swings, depression, 
troubles in learning or making decisions and memory impairments. Later it could lead to 
absence of speech, swallowing and feeding difficulties, walking problems and finally to total 
loss of independence (Ross et al., 2011). Usually patients die before the age of 60, the disease 
extending for an average of 20 years. The diagnosis can be made by a genetic test, generally 
coupled with a complete medical history and neurological and laboratory tests (Davis et al., 
1994). 
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6.2. Machado-Joseph disease clinical features 
Machado-Joseph disease (MJD) results from a mutation in the Ataxin-3 gene (ATXN3), 
with a CAG pathogenic repeat length above 55. The mutated protein inclusions are found in 
the nucleus of neurons located mainly in cerebellar dentate nuclei, basal ganglia, brain stem, 
striatum and spinal cord (Koeppen, 2005; Alves et al., 2008; Bettencourt et al., 2011). 
The clinical manifestations often include clumsiness and weakness in the arms and legs, 
spasticity, speech and swallowing difficulties, involuntary eye movements and double vision, 
which can be easily mistaken with drunkenness. Dystonia is also a common symptom, with 
abnormal posture, rigidity and repetitive moments that can be confounded with those of 
Parkinson’s disease. It eventually leads to paralysis but intellectual functions remains almost 
intact (National Institute of Neurological Disorders and Stroke, 2011). Death generally 
occurs from respiratory complications, from 6 to 30 years after onset, depending on disease 
severity. Typically it begins in mid-30s to 50 years of age and the diagnosis can be made by a 
genetic test, medical history and symptoms recognition, as well as neurological and 
laboratory tests (Matilla-Dueñas, 2012). 
 
6.3. General pathophysiology of polyglutamine diseases 
All polyglutamine diseases share common elements of pathogenesis and some of them, 
including HD and MJD, seem linked to proteolytic cleavage that liberates toxic 
polyglutamine-containing fragments. Furthermore, the expanded proteins are prone to 
aggregation, facilitating the transition to a toxic conformation (Nagai et al., 2007). It is highly 
probable that this toxicity could induce alterations in transcription, metabolism or 
impairment in stress response pathways. In a more detailed way, interactions of mutated 
protein with specific transcription factors may disturb gene expression and thus initiate 
neuronal loss.  Also, it seems to exist a direct link between the presence of mutated protein 
and mitochondrial dysfunction (Lin et al., 2006), as well as metabolic defects (Grafton  et al., 
1992). Moreover, the brain seems very susceptible to protein misfolding and protein quality 
control mechanisms appear to decline with age. Impairments in autophagy or the ubiquitin 
proteasome system could derive from age and additionally from sequestering of important 
elements from this machinery, as chaperones, by aggregated mutated proteins itself, 
compromising the stress response ability of neuronal cells (Cowan et al., 2003). 
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6.4. Current status for CSF biomarkers in HD and MJD 
Unlike the diseases described above, HD and MJD present different challenges for 
biomarkers, since they have a known cause and the diagnostic is based on a genetic test. 
However, it is also crucial to define not only the onset of these diseases, but also accurately 
track its progress, independently of the symptomatic effects from drugs (O’Keeffe  et al., 
2009). Some changes have been reported in CSF of patients suffering from HD and MJD, 
however, none has been studied systematically enough (Hersch et al. 2011). The most 
relevant studies for these diseases are summarized in Table 5. 
 
Table 5. Candidate CSF biomarkers for Huntington’s and Machado Joseph disease 
Biomarker Function Findings n (disease/control) References 
Huntington’s disease 
Leptin Metabolic hormone ↔ 15/20 Popovic et al. 2004 
Ghrelin Metabolic hormone ↔ 15/20 Popovic et al. 2004 
CART Energy homeostasis ↑ 39/28 Björkqvist et al. 2007 
Orexin A Metabolic hormone 
↔ 10/10 Gaus et al. 2005 
↔ 10/12 Meier et al. 2005 
↔ 37/30 Björkqvist et al. 2006 
Lactate Anaerobic metabolism 
↔ 11/12 Nicoli et al. 1993 
↓ 7/20 Gårseth et al. 2000 
Citrate Metabolism 
↔ 11/12 Nicoli et al. 1993 
↓ 7/20 Gårseth et al. 2000 
Pyruvate Metabolism ↑ 11/12 Nicoli et al. 1993 
Glycine Metabolism ↑ 11/12 Nicoli et al. 1993 
Glutamate Metabolism 
↓ 6/10 Kim et al. 1980 
↔ 11/12 Nicoli et al. 1993 
Nitrate NO transformation 
↔ 33/16 Milstien et al. 1994 
↑ 23/41 Boll et al. 2008 
SOD-1 Detoxification  ↓ 23/41 Boll et al. 2008 
Ceruloplasmin Iron metabolism ↓ 23/41 Boll et al. 2008 
Clusterin Apoptosis ↑ 20/9 Dalrymple et al. 2007 
NfL Axonal structure 
protein 
↑ 35/35 Constantinescu et al. 
2009 
Homovalinic 
acid 
Catecholamine 
metabolite 
↓ 15/- Caraceni et al., 1977 
↓ 8/23 Hayden et al., 1977 
↔ 51/4 Kurlan et al. 1988 
↔ 11/12 Garret et al. 1992 
↓ 20/15 Garcia Ruiz et al. 1995 
GABA Neurotransmitter 
↓ 7/9 Glaeser et al. 1975 
↓ 19/26 Enna et al. 1977 
↓ 28/5 Manyam et al. 1978 
↓ 15/19 Manyam et al. 1980 
↓ 28/30 Uhlhaas et al. 1986 
↑ 14/19 Bonnet et al. 1987 
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↔ 11/12 Nicoli et al. 1993 
Choline Metabolite ↔ 15/10 Welsch et al. 1976 
↔ 14/13 Consolo et al. 1977 
Table 5 (continued). Candidate CSF biomarkers for Huntington’s and Machado Joseph disease 
Biomarker Function Findings n (disease/control) References 
Choline Metabolite ↔ 5/22 Flentge et al. 1984 
↓ 6/9 Manyam et al. 1990a 
AChE Neurotransmitter 
↔ 5/8 Davis et al. 1979 
↓ 10/19 Ruberg et al. 1987 
↔ 6/9 Manyam et al. 1990a 
CRF Stress response ↑ 56/21 Kurlan et al. 1988a 
F2 
isoprostane 
Lipid peroxidation ↑ 20/23 Montine et al. 1999a 
Machado Joseph disease 
Substance P Neuropeptide ↓ 7/14 Matsuishi et al. 1996a 
Lactate Metabolism ↑ 7/7 Matsuishi et al. 1996b 
Pyruvate Anaerobic metabolism ↓ 7/7 Matsuishi et al. 1996b 
 
↑ increased; ↓ decreased; ↔ no significant alterations; Control refers to healthy subjects. 
CART: Cocaine and amphetamine regulated transcript; NfL: Neurofilament light chain; GABA: gamma-
Aminobutyric acid; AChE: acetylcholinesterase; CRF: Corticotropin releasing factor. 
 
The markers studied so far are mostly related with neurodegeneration general 
mechanisms, lacking specificity and reproducibility. Moreover, there is a scarcity of 
longitudinal studies for evaluation and validation of the proposed markers (Wild et al., 2008). 
For these diseases, and since the main goal is to monitor disease progression and developing 
effective therapies, it is more likely that a multiple biomarker or multiple analytes approach 
could be more successful. It is also probable that, in the future, measurements of mutant 
polyglutamine proteins in biological fluids could be used as a standard in clinical trials for 
polyglutamine diseases (Scahill et al., 2012). Some researchers pointed that endocrine 
function might be disrupted in Huntington’s and weight loss is seen in many patients. 
However, the results for biomarkers in these pathways (e.g. leptin, ghrelin, CART, orexin) 
are inconclusive so far (Popovic et al., 2004). The same is true to several biomarkers of 
mitochondrial dysfunction and increased oxidative stress. Other studies focus on 
neurotransmitter systems, particularly on GABAergic, but data interpretation is still not 
consensual, regardless of the main tendency seem to be a decrease in CSF levels (Weir et al., 
2011). For MJD, studies are even rarer with only 2 reports in CSF for substance P, lactate 
and pyruvate. Some authors refer S100b and neuron-specific enolase (NSE) as possible 
biomarker candidates in blood, but data is inconsistent as well (Tort et al., 2005; Zhou et al., 
2011). 
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7. Highlights and concluding remarks 
 
Biomarkers for neurodegenerative diseases are an urgent need, mostly giving the raise 
and prevalence of these disorders, the difficulties in diagnostic and the absence of disease-
modifying therapeutics (Kieburtz et al., 2007). In the last decade, a very large number of 
candidate biomarkers have been studied and investigated. Although these efforts and the 
developments in molecular and imaging techniques, there are no validated markers in clinical 
practice so far, with the exception of Aβ42 and tau protein measurements in CSF for 
Alzheimer’s disease. It is expected that this scenario will change in the next few years, 
primarily for Parkinson’s disease (Noelker et al. 2011). Nevertheless, some biomarkers 
already proposed are reaching an important role in management of these diseases and in the 
planning of clinical trials, a tendency that will continue to growth in the future (Gonzalez-
Cuyar et al., 2011).  
Regardless of the practicability and simplicity of blood-based biomarkers, so far results 
for this body fluid have not been reproducible, and results from diverse groups are 
significantly different. This limitation has been more easily overcome in CSF biomarkers. Due 
to its proximity to the brain tissue, CSF reflects more accurately brain metabolism, either in 
health or in disease. It is accessible by lumbar puncture, a procedure that, despite not as 
straightforward as for blood, is also safe, relatively simple and cost-effective (Mattson et al. 
2011).   
One of the major problems to overtake for the success in CSF biomarker research is the 
variability between studies, probably due to variations between techniques and procedures. 
Differences in sample collection and handling or in assay kits and protocols must be 
minimized by standard operation rules, preferentially as part of international programs and 
task forces (Bjerke et al., 2010). These joint initiatives also allow the collection of a large 
number of samples, in a multicenter perspective. Some examples of those initiatives are the 
EU Joint Programme for Neurodegenerative Disease Research, the Parkinson Progression 
Marker Initiative and the Alzheimer's Disease Neuroimaging Initiative, among others. 
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